Biomet 10-Q 14 Jan 15 2015 Q2 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	6 Months Ended
	Nov. 30, 2014	Dec. 31, 2014
Entity Information [Line Items]
Document Type	10-Q
Amendment Flag	FALSE
Document Period End Date	30-Nov-14
Document Fiscal Year Focus	2015
Document Fiscal Period Focus	Q2
Entity Registrant Name	LVB Acquisition, Inc.
Entity Central Index Key	1402366
Current Fiscal Year End Date	-26
Entity Filer Category	Non-accelerated Filer
Entity Common Stock, Shares Outstanding		552,627,862
Biomet, Inc. [Member]
Entity Information [Line Items]
Document Type	10-Q
Amendment Flag	FALSE
Document Period End Date	30-Nov-14
Document Fiscal Year Focus	2015
Document Fiscal Period Focus	Q2
Entity Registrant Name	BIOMET INC
Entity Central Index Key	351346
Current Fiscal Year End Date	-26
Entity Filer Category	Non-accelerated Filer
Entity Common Stock, Shares Outstanding		1,000

Condensed_Consolidated_Balance

Condensed Consolidated Balance Sheets (USD $)	Nov. 30, 2014	31-May-14
In Millions, unless otherwise specified
Current assets:
Cash and cash equivalents	$276.50	$247.60
Accounts receivable, less allowance for doubtful accounts receivables of $35.4 ($31.9 at May 31, 2014)	565.3	577.3
Inventories	721.7	693.4
Deferred income taxes	147	149.9
Prepaid expenses and other	187.7	202.9
Total current assets	1,898.20	1,871.10
Property, plant and equipment, net	720	716
Investments	13.5	12.5
Intangible assets, net	3,218.60	3,439.60
Goodwill	3,577.10	3,634.40
Other assets	130.7	93
Total assets	9,558.10	9,766.60
Current liabilities:
Current portion of long-term debt	132.8	133.1
Accounts payable	102.1	135.3
Accrued interest	50.7	53.4
Accrued wages and commissions	123.4	168.7
Other accrued expenses	353.6	354.7
Total current liabilities	762.6	845.2
Long-term liabilities:
Long-term debt, net of current portion	5,581.90	5,587.30
Deferred income taxes	920.3	968.6
Other long-term liabilities	259.4	256.3
Total liabilities	7,524.20	7,657.40
Commitments and contingencies
Shareholders’ equity:
Common stock	5.5	5.5
Contributed and additional paid-in capital	5,689.40	5,681.50
Accumulated deficit	-3,520	-3,617.10
Accumulated other comprehensive income (loss)	-141	39.3
Total shareholders’ equity	2,033.90	2,109.20
Total liabilities and shareholders’ equity	9,558.10	9,766.60
Biomet, Inc. [Member]
Current assets:
Cash and cash equivalents	276.5	247.6
Accounts receivable, less allowance for doubtful accounts receivables of $35.4 ($31.9 at May 31, 2014)	565.3	577.3
Inventories	721.7	693.4
Deferred income taxes	147	149.9
Prepaid expenses and other	187.7	202.9
Total current assets	1,898.20	1,871.10
Property, plant and equipment, net	720	716
Investments	13.5	12.5
Intangible assets, net	3,218.60	3,439.60
Goodwill	3,577.10	3,634.40
Other assets	130.7	93
Total assets	9,558.10	9,766.60
Current liabilities:
Current portion of long-term debt	132.8	133.1
Accounts payable	102.1	135.3
Accrued interest	50.7	53.4
Accrued wages and commissions	123.4	168.7
Other accrued expenses	353.6	354.7
Total current liabilities	762.6	845.2
Long-term liabilities:
Long-term debt, net of current portion	5,581.90	5,587.30
Deferred income taxes	920.3	968.6
Other long-term liabilities	259.4	256.3
Total liabilities	7,524.20	7,657.40
Commitments and contingencies
Shareholders’ equity:
Common stock	0	0
Contributed and additional paid-in capital	5,694.90	5,687
Accumulated deficit	-3,520	-3,617.10
Accumulated other comprehensive income (loss)	-141	39.3
Total shareholders’ equity	2,033.90	2,109.20
Total liabilities and shareholders’ equity	$9,558.10	$9,766.60

Condensed_Consolidated_Balance1

Condensed Consolidated Balance Sheets (Parenthetical) (USD $)	Nov. 30, 2014	31-May-14
In Millions, except Share data, unless otherwise specified
Allowance for doubtful receivables	$35.40	$31.90
Common stock, par value	$0.01	$0.01
Common stock, shares authorized	740,000,000	740,000,000
Common stock, shares issued	552,552,033	552,484,996
Common stock, shares outstanding	552,522,033	552,484,996
Biomet, Inc. [Member]
Allowance for doubtful receivables	$35.40	$31.90
Common stock, par value	$0	$0
Common stock, shares authorized	1,000	1,000
Common stock, shares issued	1,000	1,000
Common stock, shares outstanding	1,000	1,000

Condensed_Consolidated_Stateme

Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) (USD $)	3 Months Ended		6 Months Ended
In Millions, unless otherwise specified	Nov. 30, 2014	Nov. 30, 2013	Nov. 30, 2014	Nov. 30, 2013
Net sales	$843.60	$825.70	$1,618.40	$1,556.40
Cost of sales	183.8	255.1	399.7	463.1
Gross profit	659.8	570.6	1,218.70	1,093.30
Selling, general and administrative expense	367.7	340.4	729.4	653.7
Research and development expense	42.9	41.4	85.7	78.9
Amortization	79.6	75.2	151.5	150.7
Operating income	169.6	113.6	252.1	210
Interest expense	78.5	105.7	158.6	193.3
Other (income) expense	-2.1	3.7	-6.3	5.9
Other expense, net	76.4	109.4	152.3	199.2
Income before income taxes	93.2	4.2	99.8	10.8
Provision (benefit) from income taxes	3.4	-0.7	2.7	-25.2
Net income	89.8	4.9	97.1	36
Other comprehensive income (loss), net of tax:
Change in unrealized holding value on available-for-sale securities	0	1.3	0.1	1.3
Interest rate swap unrealized gains (losses)	-0.4	8.8	3.2	22.3
Foreign currency related gains (losses)	-137.3	27.2	-185.5	31.7
Unrecognized actuarial gains (losses)	1.6	-0.2	1.9	0
Other comprehensive income (loss)	-136.1	37.1	-180.3	55.3
Comprehensive income (loss)	-46.3	42	-83.2	91.3
Biomet, Inc. [Member]
Net sales	843.6	825.7	1,618.40	1,556.40
Cost of sales	183.8	255.1	399.7	463.1
Gross profit	659.8	570.6	1,218.70	1,093.30
Selling, general and administrative expense	367.7	340.4	729.4	653.7
Research and development expense	42.9	41.4	85.7	78.9
Amortization	79.6	75.2	151.5	150.7
Operating income	169.6	113.6	252.1	210
Interest expense	78.5	105.7	158.6	193.3
Other (income) expense	-2.1	3.7	-6.3	5.9
Other expense, net	76.4	109.4	152.3	199.2
Income before income taxes	93.2	4.2	99.8	10.8
Provision (benefit) from income taxes	3.4	-0.7	2.7	-25.2
Net income	89.8	4.9	97.1	36
Other comprehensive income (loss), net of tax:
Change in unrealized holding value on available-for-sale securities	0	1.3	0.1	1.3
Interest rate swap unrealized gains (losses)	-0.4	8.8	3.2	22.3
Foreign currency related gains (losses)	-137.3	27.2	-185.5	31.7
Unrecognized actuarial gains (losses)	1.6	-0.2	1.9	0
Other comprehensive income (loss)	-136.1	37.1	-180.3	55.3
Comprehensive income (loss)	($46.30)	$42	($83.20)	$91.30

Condensed_Consolidated_Stateme1

Condensed Consolidated Statements of Cash Flows (USD $)	6 Months Ended
In Millions, unless otherwise specified	Nov. 30, 2014	Nov. 30, 2013
Cash flows provided by (used in) operating activities:
Net income	$97.10	$36
Adjustments to reconcile net loss to net cash provided by operating activities:
Depreciation and amortization	249.1	242.5
Amortization and write off of deferred financing costs	5.6	14.4
Stock-based compensation expense	7.6	8.6
Provision for (recovery) of doubtful accounts receivable	-0.3	1.1
Litigation recoveries	-48.3	0
Deferred income taxes	-47.9	-103.1
Other	0.8	-7.3
Changes in operating assets and liabilities, net of acquired assets:
Accounts receivable	-12.3	-39.3
Inventories	-43.5	-28
Prepaid expenses	17	10
Accounts payable	-30	-21
Income taxes	68.4	10.7
Accrued interest	-2.7	1.3
Accrued wages and commissions	-39.8	-31
Accrued expenses and other	-58.1	76
Net cash provided by operating activities	162.7	170.9
Cash flows provided by (used in) investing activities:
Proceeds from sales/maturities of investments	15.2	19
Purchases of investments	-16.3	-19.6
Net proceeds from sale of assets	0	0.1
Capital expenditures	-132.1	-98.5
Acquisitions, net of cash acquired	-0.6	-0.8
Net cash used in investing activities	-133.8	-248.6
Debt:
Payments under European facilities	0	-2.3
Payments under senior secured credit facilities	-8	-14.9
Proceeds under revolvers	205	159.3
Payments under revolvers	-20	-7
Proceeds from senior notes due 2020 and term loans	0	870.5
Retirement of term loans	-180	-1,091.60
Payment of fees related to refinancing activities	0	-15.5
Equity:
Option exercises	0.3	0.3
Net cash provided by (used in) financing activities	-2.7	-101.2
Effect of exchange rate changes on cash	2.7	-0.5
Increase (decrease) in cash and cash equivalents	28.9	-179.4
Cash and cash equivalents, beginning of period	247.6	355.6
Cash and cash equivalents, end of period	276.5	176.2
Supplemental disclosures of cash flow information:
Interest	155.5	186.6
Income taxes	-33.1	65.2
Biomet, Inc. [Member]
Cash flows provided by (used in) operating activities:
Net income	97.1	36
Adjustments to reconcile net loss to net cash provided by operating activities:
Depreciation and amortization	249.1	242.5
Amortization and write off of deferred financing costs	5.6	14.4
Stock-based compensation expense	7.6	8.6
Provision for (recovery) of doubtful accounts receivable	-0.3	1.1
Litigation recoveries	-48.3	0
Deferred income taxes	-47.9	-103.1
Other	0.8	-7.3
Changes in operating assets and liabilities, net of acquired assets:
Accounts receivable	-12.3	-39.3
Inventories	-43.5	-28
Prepaid expenses	17	10
Accounts payable	-30	-21
Income taxes	68.4	10.7
Accrued interest	-2.7	1.3
Accrued wages and commissions	-39.8	-31
Accrued expenses and other	-58.1	76
Net cash provided by operating activities	162.7	170.9
Cash flows provided by (used in) investing activities:
Proceeds from sales/maturities of investments	15.2	19
Purchases of investments	-16.3	-19.6
Net proceeds from sale of assets	0	0.1
Capital expenditures	-132.1	-98.5
Acquisitions, net of cash acquired	-0.6	-0.8
Net cash used in investing activities	-133.8	-248.6
Debt:
Payments under European facilities	0	-2.3
Payments under senior secured credit facilities	-8	-14.9
Proceeds under revolvers	205	159.3
Payments under revolvers	-20	-7
Proceeds from senior notes due 2020 and term loans	0	870.5
Retirement of term loans	-180	-1,091.60
Payment of fees related to refinancing activities	0	-15.5
Equity:
Option exercises	0.3	0.3
Net cash provided by (used in) financing activities	-2.7	-101.2
Effect of exchange rate changes on cash	2.7	-0.5
Increase (decrease) in cash and cash equivalents	28.9	-179.4
Cash and cash equivalents, beginning of period	247.6	355.6
Cash and cash equivalents, end of period	276.5	176.2
Supplemental disclosures of cash flow information:
Interest	155.5	186.6
Income taxes	-33.1	65.2
Lanx, Inc. [Member]
Adjustments to reconcile net loss to net cash provided by operating activities:
Depreciation and amortization		1.9
Cash flows provided by (used in) investing activities:
Acquisitions, net of cash acquired	0	-148.8
Lanx, Inc. [Member] | Biomet, Inc. [Member]
Cash flows provided by (used in) investing activities:
Acquisitions, net of cash acquired	$0	($148.80)

Basis_of_Presentation

Basis of Presentation	6 Months Ended
	Nov. 30, 2014
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation	Basis of Presentation.
	The accompanying unaudited condensed consolidated financial statements include the accounts of LVB Acquisition, Inc. (“LVB” and “Parent”) and Biomet, Inc. and its subsidiaries (individually and collectively with its subsidiaries referred to as “Biomet”, and together with LVB, the “Company”, “we”, “us” or “our”). Biomet is a wholly-owned subsidiary of LVB. LVB has no other operations beyond its ownership of Biomet. Intercompany accounts and transactions have been eliminated in consolidation.
	The unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for condensed financial information, the instructions to Form 10-Q and Article 10 of Regulation S-X. As a result, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation of the financial condition, results of operations and cash flows for the periods presented have been included. Operating results for the three and six months ended November 30, 2014 are not necessarily indicative of the results that may be expected for the fiscal year ending May 31, 2015. For further information, including the Company’s significant accounting policies, refer to the audited consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended May 31, 2014 (the “2014 Form 10-K”).
	The May 31, 2014 condensed consolidated balances have been derived from the audited financial statements included in the 2014 Form 10-K.
	Zimmer Merger
	On April 24, 2014, LVB, a Delaware corporation, which owns all of the outstanding shares of common stock of Biomet, Inc., entered into an Agreement and Plan of Merger (the “Merger Agreement”), with Zimmer Holdings, Inc., a Delaware corporation, and Owl Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Zimmer. Zimmer and LVB currently expect to complete the merger in the first quarter of 2015, subject to the receipt of regulatory approvals and the satisfaction or waiver of the other conditions to the merger contained in the Merger Agreement. However, it is possible that factors outside the control of Zimmer and LVB could require Zimmer and LVB to complete the merger at a later date or not complete it at all.
	LVB Acquisition Holding, LLC (“Holdings”) and the Principal Stockholders (as defined below) have entered into a voting agreement with Zimmer (the “Voting Agreement”). Under the Voting Agreement, Holdings agreed to execute and deliver a written consent with respect to the shares of LVB common stock owned by it, adopting the Merger Agreement and approving the merger. On October 3, 2014 Holdings executed and delivered a written consent adopting the Merger Agreement and approving the merger with respect to the 536,034,330 shares, or approximately 97%, of our common stock outstanding on the record date for the consent, September 19, 2014. As such, we have received written consents sufficient to approve our proposed merger with Zimmer.
	Under the Merger Agreement, LVB will be acquired for an aggregate purchase price based on a total enterprise value of $13.35 billion, which will consist of $10.35 billion in cash (which is subject to adjustment) and 32,704,677 shares of Zimmer common stock (which number of shares represents the quotient of $3.0 billion divided by $91.73, the volume weighted average price of Zimmer’s common stock on the New York Stock Exchange for the five trading days prior to the date of the Merger Agreement). According to Zimmer’s Form 10-Q filed on November 5, 2014, in connection with the merger, Zimmer expects to pay off all of the outstanding funded debt of LVB, totaling $5,714.7 million as of November 30, 2014 and its subsidiaries, and the aggregate cash merger consideration paid by Zimmer at the closing will be reduced by such amount. Zimmer is expected to fund the cash portion of the merger consideration and the repayment of the outstanding funded debt of LVB and its subsidiaries with a combination of new debt and cash on hand. The closing of the merger is not conditioned on the receipt of any debt financing by Zimmer. Zimmer, however, is not required to consummate the merger until the completion of a 15 consecutive business day marketing period.
	Recent Accounting Pronouncements
	Revenue—In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers (Topic 606). This update provides a comprehensive new revenue recognition model that requires a company to recognize revenue to depict the transfer of goods or services to a customer at an amount that reflects the consideration it expects to receive in exchange for those goods or services. The guidance also requires additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts. This update is effective for annual and interim periods beginning after December 15, 2016. Early application is not permitted. This update permits the use of either the retrospective or cumulative effect transition method. The Company is currently evaluating the impact this ASU will have on its financial position, results of operations or cash flows.

Recent_Acquisitions_by_Biomet

Recent Acquisitions by Biomet	6 Months Ended
	Nov. 30, 2014
Business Combinations [Abstract]
Recent Acquisitions by Biomet	Recent Acquisitions by Biomet.
	2013 Spine Acquisition
	On October 5, 2013, the Company and its wholly-owned subsidiaries EBI Holdings, LLC, a Delaware limited liability company (“EBI”), and LNX Acquisition, Inc., a Delaware corporation (“Merger Sub Lanx”), entered into an Agreement and Plan of Merger with Lanx, Inc., a Delaware corporation (“Lanx”). On October 31, 2013, Merger Sub Lanx merged with and into Lanx and the separate corporate existence of Merger Sub Lanx ceased (the “Lanx Merger”). Upon the consummation of the Lanx Merger, Lanx became a wholly-owned subsidiary of EBI and the Company (“2013 Spine Acquisition”). As of November 1, 2013, the activities of Lanx were included in the Company’s consolidated results. The aggregate purchase price for the acquisition was approximately $150.8 million on a debt-free basis. The Company acquired Lanx to strengthen its spine product portfolio, as well as integrate and focus its distribution network to grow the spine business.
	The acquisition has been accounted for as a business combination. The purchase price was allocated to the acquired assets and liabilities based on the estimated fair value of the acquired assets at the date of acquisition. As of November 30, 2014, the Company recorded the final allocation of the purchase price to acquired tangible and identifiable intangible assets and liabilities based on their fair value at the initial acquisition date.
	The following table summarizes the purchase price allocation:
	(in millions)
	Cash	$	2
	Accounts receivable	16.5
	Inventory	24.8
	Prepaid expenses and other	11
	Instruments	9.9
	Other property, plant and equipment	2.1
	Deferred tax liability	(36.8		)
	Other liabilities assumed	(20.7		)
	Intangible assets	102.3
	Goodwill	39.7
	Purchase price	$	150.8
	The results of operations of the business have been included subsequent to the October 31, 2013 closing date in the accompanying consolidated financial statements. The intangible assets are allocated to core technology, corporate trade names, distributors, product trade names and customer relationships. The goodwill arising from the acquisition consists largely of the synergies and economies of scale from combining operations as well as the value of the workforce. All of the intangible assets and goodwill were assigned to the spine and bone healing reporting unit. The goodwill value is not expected to be tax deductible.
	The following pro forma financial information summarizes the combined results of the Company and Lanx, which assumes that they were combined as of the beginning of the Company’s fiscal year 2013.
	The unaudited pro forma financial information for the combined entity is as follows:
		Three Months Ended			Six Months Ended
	(in millions)	30-Nov-13			November 30, 2013
	Net sales	$	841.5		$	1,595.30
	Net income	$	7.6		$	35.2
	Pro forma adjustments have been made to the historical financial statements to account for those items directly attributable to the transaction and to include only adjustments which have a continuing impact. Pro forma adjustments include the incremental amortization and depreciation of assets of $0.8 million and $1.9 million for the three and six months ended November 30, 2013, respectively. The pro forma financial information also reflects the elimination of $4.1 million of transaction costs directly attributable to the acquisition. Adjustments reflect the elimination of the historical interest expense of Lanx as the transaction was a debt-free transaction. All pro forma adjustments were calculated with no tax impact due to the historical and acquired net operating losses.

Inventories

Inventories	6 Months Ended
	Nov. 30, 2014
Inventory Disclosure [Abstract]
Inventories	Inventories.
	Inventories are stated at the lower of cost or market, with cost determined under the first-in, first-out method. The Company reviews inventory on hand and writes down excess and slow-moving inventory based on an assessment of future demand and historical experience. Inventories consisted of the following:
	(in millions)	30-Nov-14		May 31, 2014
	Raw materials	$	91.3	$	83.1
	Work-in-process	48.2		54.4
	Finished goods	582.2		555.9
	Inventories	$	721.7	$	693.4

Property_Plant_and_Equipment

Property, Plant and Equipment	6 Months Ended
	Nov. 30, 2014
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment	Property, Plant and Equipment.
	Property, plant and equipment are carried at cost less accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful life of the asset. Related maintenance and repairs are expensed as incurred.
	The Company reviews property, plant and equipment for impairment whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. An impairment loss would be recognized when estimated undiscounted future cash flows relating to the asset, or asset group, are less than its carrying value, with the amount of the loss equal to the excess of carrying value of the asset, or asset group, over the estimated fair value.
	Useful lives by major product category consisted of the following:
		Useful life
	Land improvements	20 years
	Buildings and leasehold improvements	30 years
	Machinery and equipment	5-10 years
	Instruments	4 years
	Property, plant and equipment consisted of the following:
	(in millions)	30-Nov-14			May 31, 2014
	Land and land improvements	$	40.4		$	40.8
	Buildings and leasehold improvements	124.5			126.8
	Machinery and equipment	431.2			414.5
	Instruments	814.2			791.9
	Construction in progress	36.1			47.9
	Total property, plant and equipment	1,446.40			1,421.90
	Accumulated depreciation	(726.4		)	(705.9		)
	Total property, plant and equipment, net	$	720		$	716
	The Company recorded depreciation expense of $47.9 million and $46.9 million for the three months ended November 30, 2014 and 2013, respectively, and $97.6 million and $91.8 million for the six months ended November 30, 2014 and 2013, respectively.

Investments

Investments	6 Months Ended
	Nov. 30, 2014
Investments, Debt and Equity Securities [Abstract]
Investments	Investments.
	At November 30, 2014, the Company’s investment securities were classified as follows:
		Amortized		Unrealized					Fair
	(in millions)	Cost		Gains		Losses			Value
	Available-for-sale:
	Equity securities	$	0.5	$	0.1	$	—		$	0.6
	Time deposit	10.2		—		(0.1		)	10.1
	Total available-for-sale investments	$	10.7	$	0.1	$	(0.1	)	$	10.7
		Amortized		Realized					Fair
		Cost		Gains		Losses			Value
	Trading:
	Equity securities	$	2.7	$	0.1	$	—		$	2.8
	Total trading investments	$	2.7	$	0.1	$	—		$	2.8
	At May 31, 2014, the Company’s investment securities were classified as follows:
		Amortized		Unrealized					Fair
	(in millions)	Cost		Gains		Losses			Value
	Available-for-sale:
	Equity securities	$	0.2	$	0.6	$	(0.3	)	$	0.5
	Time deposit	10.2		—		—			10.2
	Total available-for-sale investments	$	10.4	$	0.6	$	(0.3	)	$	10.7
		Amortized		Realized					Fair
		Cost		Gains		Losses			Value
	Trading:
	Equity securities	$	1.6	$	0.3	$	(0.1	)	$	1.8
	Total trading investments	$	1.6	$	0.3	$	(0.1	)	$	1.8
	The Company recorded proceeds on the sales/maturities of investments of $15.2 million and $9.5 million during the three months ended November 31, 2014 and 2013, respectively, and $15.2 million and $19.0 million during the six months ended November 30, 2014 and 2013, respectively. The Company purchased investments of $10.1 million during the three months ended November 30, 2013, with no purchases during the three months ended November 30, 2014, and $16.3 million and $19.6 million during the six months ended November 30, 2014 and 2013, respectively.

Goodwill_and_Other_Intangible_

Goodwill and Other Intangible Assets	6 Months Ended
	Nov. 30, 2014
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Other Intangible Assets	Goodwill and Other Intangible Assets.
	The balance of goodwill as of November 30, 2014 and May 31, 2014 was $3,577.1 million and $3,634.4 million, respectively. The change in goodwill is primarily related to foreign currency fluctuations.
	The Company uses an accelerated method for amortizing customer relationship intangibles, as the value for those relationships is greater at the beginning of their life. The accelerated method was calculated using historical customer attrition rates. The remaining finite-lived intangibles are amortized on a straight line basis. The decrease in the net intangible asset balance is primarily due to amortization.
	The Company performs its annual assessment for impairment as of March 31 for all reporting units, or on an interim basis if an event occurs or circumstances change that would more likely than not reduce the fair value of a reporting unit below its carrying amount. The estimates and assumptions underlying the fair value calculations used in the Company’s annual impairment tests are uncertain by their nature and can vary significantly from actual results. Factors that management must estimate include, but are not limited to, industry and market conditions, sales volume and pricing, raw material costs, capital expenditures, working capital changes, cost of capital, and tax rates. These factors are especially difficult to predict when global financial markets are volatile. The estimates and assumptions used in its impairment tests are consistent with those the Company uses in its internal planning. These estimates and assumptions may change from period to period. If the Company uses different estimates and assumptions in the future, impairment charges may occur and could be material.
	Intangible assets consisted of the following at November 30, 2014 and May 31, 2014:
	(in millions)	November 30, 2014
		Gross					Net
		Carrying		Accumulated			Carrying
		Amount		Amortization			Amount
	Core technology	$	1,748.90	$	(605.4	)	$	1,143.50
	Completed technology	662.7		(281.3		)	381.4
	Product trade names	188.8		(80.4		)	108.4
	Customer relationships	2,304.70		(1,021.1		)	1,283.60
	Non-compete contracts	4.9		(4.6		)	0.3
	Sub-total	4,910.00		(1,992.8		)	2,917.20
	Corporate trade names	301.4		—			301.4
	Total	$	5,211.40	$	(1,992.8	)	$	3,218.60
	(in millions)	May 31, 2014
		Gross					Net
		Carrying		Accumulated			Carrying
		Amount		Amortization			Amount
	Core technology	$	1,743.30	$	(569.8	)	$	1,173.50
	Completed technology	672		(262.1		)	409.9
	Product trade names	208.1		(77.6		)	130.5
	Customer relationships	2,371.60		(955.9		)	1,415.70
	Non-compete contracts	4.9		(4.6		)	0.3
	Sub-total	4,999.90		(1,870.0		)	3,129.90
	Corporate trade names	309.7		—			309.7
	Total	$	5,309.60	$	(1,870.0	)	$	3,439.60
	The weighted average useful life of the intangibles at November 30, 2014 is as follows:
		Weighted Average
		Useful Life
	Core technology	14 years
	Completed technology	8 years
	Product trade names	12 years
	Customer relationships	13 years
	Non-compete contracts	1 year
	Corporate trade names	Indefinite life
	Expected amortization expense for the intangible assets stated above for the years ending May 31, 2015 through 2019 is $278.2 million, $273.3 million, $269.6 million, $252.3 million, and $246.3 million, respectively.

Debt

Debt	6 Months Ended
	Nov. 30, 2014
Debt Disclosure [Abstract]
Debt	Debt.
	The terms and carrying value of each debt instrument at November 30, 2014 and May 31, 2014 are set forth below:
	(U.S. dollars in millions)	Maturity Date	Interest Rate	Currency	30-Nov-14		May 31, 2014
	Debt Instruments
	Term loan facility B	March 25, 2015	LIBOR + 3.00%	USD	$	102.7	$	103.3
	Term loan facility B-1	July 25, 2017	LIBOR + 3.50%	USD	$	2,772.20	$	2,959.60
	Cash flow revolving credit facility	April 25, 2017	LIBOR + 3.50%	USD	$	—	$	—
	Cash flow revolving credit facility	April 25, 2017	LIBOR + 3.50%	USD/EUR	$	—	$	—
	Asset-based revolving credit facility	July 25, 2017	LIBOR + 2.00%	USD	$	185	$	—
	Senior notes	August 1, 2020	6.50%	USD	$	1,825.00	$	1,825.00
	Senior subordinated notes	October 1, 2020	6.50%	USD	$	800	$	800
	Premium on notes				$	29.8	$	32.5
	Total debt				$	5,714.70	$	5,720.40
	The Company has the option to choose the frequency with which it resets and pays interest on its term loans. The Company currently pays interest on the majority of its term loans and interest rate swaps each month. The remaining term loan and swap interest is paid quarterly. Interest on the 6.500% senior notes due 2020 is paid semiannually in February and August. Interest on the 6.500% senior subordinated notes due 2020 is paid semiannually in April and October.
	The Company currently elects to use 1-month LIBOR for setting the interest rates on 100% of its U.S. dollar-denominated term loans. The 1-month LIBOR rate for the majority of the U.S. dollar-denominated term loan and asset-based revolver as of November 30, 2014 was 0.16%. The Company’s term loan facilities require payments each year in an amount equal to (x) 0.25%of the product of (i) the aggregate principal amount of all dollar-denominated term loans outstanding under the original credit agreement on the closing date multiplied by (ii) a fraction, the numerator of which is the aggregate principal amount of dollar-denominated term B loans outstanding on August 2, 2012 (after giving effect to certain conversions to occur on or after August 2, 2012 pursuant to the amended and restated credit agreement) and the denominator of which is the aggregate principal amount of all outstanding term loans on August 2, 2012 and (y) 0.25% of the aggregate principal amount of all outstanding dollar-denominated term B-1 loans, in each case in equal calendar quarterly installments until maturity of the loan and after giving effect to the application of any prepayments. The total amount of required payments under the Company’s term loan facilities was $8.0 million for the six months ended November 30, 2014. The cash flow and asset-based revolving credit facilities and the notes do not have terms for mandatory principal paydowns.
	The Company’s revolving borrowing base available under all debt facilities at November 30, 2014 was $494.8 million, which is net of the borrowing base limitations relating to the asset-based revolving credit facility and outstanding balances of $185.0 million under the asset-based revolving credit facility.
	As of November 30, 2014, $62.7 million of financing fees related to the Company’s credit agreement and refinancing remain in long-term assets and continue to be amortized through interest expense over the remaining life of the credit agreement and new debt instruments.
	Each of Biomet, Inc.’s existing wholly-owned domestic subsidiaries fully, unconditionally, jointly, and severally guarantee the 6.500% senior notes due 2020 on a senior unsecured basis and the 6.500% senior subordinated notes due 2020 on a senior subordinated unsecured basis, in each case to the extent such subsidiaries guarantee Biomet, Inc.’s senior secured credit facilities. LVB Acquisition, Inc. is neither an issuer nor guarantor of the notes described within this footnote.
	Retirement of euro-denominated Term Loan and Repricing of U.S. dollar-denominated Term B-1 Loan
	On September 10, 2013, Biomet retired €167.3 million ($221.4 million) principal amount of its euro-denominated term loan using cash on hand. On September 25, 2013, Biomet completed an $870.5 million U.S. dollar-denominated term loan offering, the proceeds of which were used to retire the remaining euro-denominated term loan principal balance of €657.7 million ($870.2 million). Concurrently with the new $870.5 million U.S. dollar-denominated term loan offering, Biomet also completed a repricing of its existing $2,111.4 million extended U.S. dollar-denominated term loan to LIBOR + 3.50%. The terms of the new term loan are consistent with the existing extended U.S. dollar-denominated term loan.

Fair_Value_Measurements

Fair Value Measurements	6 Months Ended
	Nov. 30, 2014
Fair Value Disclosures [Abstract]
Fair Value Measurements	Fair Value Measurements.
	Assets and Liabilities Measured at Fair Value on a Recurring Basis
	Fair value measurements are principally applied to (1) financial assets and liabilities such as marketable equity securities and debt securities, (2) investments in equity and other securities and (3) derivative instruments consisting of interest rate swaps. These items are marked-to-market at each reporting period to fair value. The information in the following paragraphs and tables primarily addresses matters relative to these financial assets and liabilities.
	•	Level 1—Inputs are quoted prices in active markets for identical assets or liabilities. The Company’s Level 1 assets include money market investments and marketable equity securities.
	•	Level 2—Inputs include quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active and inputs (other than quoted prices) that are observable for the asset or liability, either directly or indirectly. The Company’s Level 2 assets and liabilities primarily include time deposits, interest rate swaps, pension plan assets (equity securities, debt securities and other) and foreign currency exchange contracts whose value is determined using a pricing model with inputs that are observable in the market or can be derived principally from or corroborated by observable market data.
	•	Level 3—Inputs are unobservable for the asset or liability. The Company’s Level 3 assets include other equity investments. See the section below titled Level 3 Valuation Techniques for further discussion of how the Company determines fair value for investments classified as Level 3.
	The following table provides information by level for assets and liabilities that are measured at fair value on a recurring basis at November 30, 2014 and May 31, 2014:
				Fair Value Measurements
		Fair Value at		Using Inputs Considered as
	(in millions)	November 30, 2014		Level 1		Level 2		Level 3
	Assets:
	Money market funds	$	124.6	$	124.6	$	—	$	—
	Time deposits	10.2		—		10.2		—
	Pension plan assets	144.9		—		129.9		15
	Foreign currency exchange contracts	6		—		6		—
	Equity securities	3.4		3.2		—		0.2
	Total assets	$	289.1	$	127.8	$	146.1	$	15.2
	Liabilities:
	Interest rate swaps	$	15.5	$	—	$	15.5	$	—
	Foreign currency exchange contracts	0.4		—		0.4		—
	Total liabilities	$	15.9	$	—	$	15.9	$	—
				Fair Value Measurements
		Fair Value at		Using Inputs Considered as
	(in millions)	May 31, 2014		Level 1		Level 2		Level 3
	Assets:
	Money market funds	$	145	$	145	$	—	$	—
	Time deposits	25.8		—		25.8		—
	Pension plan assets	147.5		—		132.5		15
	Foreign currency exchange contracts	1.1		—		1.1		—
	Equity securities	0.5		0.3		—		0.2
	Total assets	$	319.9	$	145.3	$	159.4	$	15.2
	Liabilities:
	Interest rate swaps	$	20.2	$	—	$	20.2	$	—
	Foreign currency exchange contracts	1.3		—		1.3		—
	Total liabilities	$	21.5	$	—	$	21.5	$	—
	Level 3 Valuation Techniques
	Financial assets are considered Level 3 when their fair values are determined using pricing models, discounted cash flow methodologies or similar techniques and at least one significant model assumption or input is unobservable. Level 3 financial assets also include certain investment securities for which there is limited market activity where the determination of fair value requires significant judgment or estimation. Level 3 investment securities primarily include other equity investments for which there was a decrease in the observation of market pricing. As of November 30, 2014 and May 31, 2014, these securities were valued primarily using internal cash flow valuation that incorporates transaction details such as contractual terms, maturity, timing and amount of future cash flows, as well as assumptions about liquidity and credit valuation adjustments of marketplace participants.
	The estimated fair value of the Company’s long-term debt, including the current portion, at November 30, 2014 and May 31, 2014 was $5,846.9 million and $5,912.9 million, respectively, compared to carrying values of $5,714.7 million and $5,720.4 million, respectively. The fair value of the Company’s traded debt is considered Level 3 and was estimated using quoted market prices for the same or similar instruments, among other inputs. The fair value of the Company’s variable rate term debt was estimated using Bloomberg composite quotes. In determining the fair values and carrying values, the Company considers the terms of the related debt and excludes the impacts of debt discounts and interest rate swaps.
	Assets and Liabilities that are Measured at Fair Value on a Nonrecurring Basis
	During the three and six months ended November 30, 2014 and 2013, the Company had no significant measurements of assets or liabilities at fair value on a nonrecurring basis subsequent to their initial recognition.

Derivative_Instruments_and_Hed

Derivative Instruments and Hedging Activities	6 Months Ended
	Nov. 30, 2014
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivative Instruments and Hedging Activities	Derivative Instruments and Hedging Activities.
	The Company is exposed to certain market risks relating to its ongoing business operations, including foreign currency risk, interest rate risk and commodity price risk. The Company currently manages foreign currency risk and interest rate risk through the use of derivatives.
	Derivatives Designated as Hedging Instruments
	Interest Rate Instruments—The Company uses interest rate swap agreements (cash flow hedges) in U.S. dollars as a means of fixing the interest rate on portions of its floating-rate debt instruments. As of November 30, 2014, the Company had a swap liability of $15.5 million, which consisted of $6.7 million short-term and $9.0 million long-term, partially offset by a $0.2 million credit valuation adjustment. As of May 31, 2014, the Company had a swap liability of $20.2 million, which consisted of $8.8 million short-term and $11.6 million long-term, partially offset by a $0.2 million credit valuation adjustment.
	The table below summarizes existing swap agreements at November 30, 2014 and May 31, 2014:
	(in millions)										Fair Value at				Fair Value at
				Notional							30-Nov-14				May 31, 2014
	Structure	Currency		Amount				Effective Date	Termination Date		Asset (Liability)				Asset (Liability)
	5 years	USD		$	195			September 25, 2009	September 25, 2014		$	—			$	(1.7	)
	2 years	USD		190				March 25, 2013	March 25, 2015		(0.4		)		(1.0		)
	3 years	USD		270				December 27, 2013	September 25, 2016		(4.7		)		(5.8		)
	5 years	USD		350				September 25, 2012	September 25, 2017		(5.3		)		(6.0		)
	5 years	USD		350				September 25, 2012	September 25, 2017		(5.3		)		(5.9		)
	Credit valuation adjustment										0.2				0.2
	Total interest rate instruments										$	(15.5	)		$	(20.2	)
	The interest rate swaps are recorded in other accrued expenses and other long-term liabilities. As a result of cash flow hedge treatment being applied, all unrealized gains and losses related to the derivative instruments are recorded in accumulated other comprehensive income (loss). Hedge effectiveness is tested quarterly to determine if hedge treatment is still appropriate. The tables below summarize the effective portion and ineffective portion of the Company’s interest rate swaps before tax for the three and six months ended November 30, 2014 and 2013:
	(in millions)	Three Months Ended							Six Months Ended
	Derivatives in cash flow hedging relationship	30-Nov-14				30-Nov-13			30-Nov-14				30-Nov-13
	Interest rate swaps:
	Amount of gain (loss) recognized in OCI	$	(0.6	)		$	4.5		$	4.7			$	26.2
	Amount of (gain) loss reclassified from accumulated OCI into interest expense (effective portion)	2.5				6.8			7.3				14.3
	Amount (gain) loss recognized in other income (expense) (ineffective portion and amount excluded from effectiveness testing)	—				21.8			—				21.8
	As of November 30, 2014, the effective interest rate, including the applicable lending margin, on 41.84% ($1,160.0 million) of the outstanding principal of the Company’s U.S. dollar term loan was fixed at 4.84% through the use of interest rate swaps. The remaining unhedged balances of the U.S. dollar term loans had an effective interest rate of 3.62%. As of November 30, 2014 and May 31, 2014, the Company’s effective weighted average interest rate on all outstanding debt, including the interest rate swaps, was 5.15% and 5.37%, respectively.
	Derivatives Not Designated as Hedging Instruments
	Foreign Currency Instruments—The Company faces transactional currency exposures that arise when it or its foreign subsidiaries enter into transactions, primarily on an intercompany basis, denominated in currencies other than their functional currency. The Company may enter into short-term forward currency exchange contracts in order to mitigate the currency exposure related to these intercompany payables and receivables arising from intercompany trade. The Company does not designate these contracts as hedges; therefore, all forward currency exchange contracts are recorded at their fair value each period, with the resulting gains and losses recorded in other (income) expense. Any foreign currency remeasurement gains or losses recognized in a period are generally offset with gains or losses on the forward currency exchange contracts. As of November 30, 2014, the fair value of the Company’s derivatives not designated as hedging instruments on a gross basis were assets of $6.0 million recorded in prepaid expenses and other, and liabilities of $0.4 million recorded in other accrued expenses. As of May 31, 2014, the fair value of the Company’s derivatives not designated as hedging instruments on a gross basis were assets of $1.1 million recorded in prepaid expenses and other, and liabilities of $1.3 million recorded in other accrued expenses.

Accumulated_Other_Comprehensiv

Accumulated Other Comprehensive Income (Loss)	6 Months Ended
	Nov. 30, 2014
Equity [Abstract]
Accumulated Other Comprehensive Income (Loss)	Accumulated Other Comprehensive Income (Loss).
	Accumulated other comprehensive income (loss) includes currency translation adjustments, certain derivative-related activity, changes in the value of available-for-sale investments and changes in pension assets. The Company generally deems its foreign investments to be essentially permanent in nature and does not provide for taxes on currency translation adjustments arising from translating the investment in a foreign currency to U.S. dollars. When the Company determines that a foreign investment is no longer permanent in nature, estimated taxes are provided for the related deferred tax liability (asset), if any, resulting from currency translation adjustments.
	Accumulated other comprehensive income (loss) and the related components, net of tax, are included in the table below:
	(in millions)	Unrecognized actuarial gains (losses)			Foreign currency translation adjustments			Unrealized gain (loss) on interest rate swaps			Unrealized gain (loss) on available-for-sale securities			Accumulated other comprehensive income (loss)
	31-May-14	$	(11.0	)	$	62.6		$	(12.3	)	$	—		$	39.3
	OCI before reclassifications	1.9			(185.5		)	(1.4		)	0.1			(184.9		)
	Reclassifications	—			—			4.6			—			4.6
	30-Nov-14	$	(9.1	)	$	(122.9	)	$	(9.1	)	$	0.1		$	(141.0	)
	Reclassification adjustments from OCI are included in the table below:
	(in millions)	Three Months Ended November 30, 2014			Three Months Ended November 30, 2013			Six Months Ended November 30, 2014			Six Months Ended November 30, 2013			Location on Statement of Operations
	Interest rate swaps	$	2.5		$	28.6		$	7.3		$	36.1		Interest expense
	The tax effects in other comprehensive income (loss) are included in the tables below:
		Three Months Ended November 30, 2014									Three Months Ended November 30, 2013
	(in millions)	Before Tax			Tax			Net of Tax			Before Tax			Tax			Net of Tax
	Unrecognized actuarial gains (losses)	$	2.3		$	(0.7	)	$	1.6		$	(0.2	)	$	—		$	(0.2	)
	Foreign currency translation adjustments	(152.0		)	14.7			(137.3		)	26			1.2			27.2
	Unrealized gain (loss) on interest rate swaps	(2.7		)	0.7			(2.0		)	(18.1		)	9.1			(9.0		)
	Reclassifications on interest rate swaps	2.5			(0.9		)	1.6			28.6			(10.8		)	17.8
	Unrealized gain (loss) on available-for-sale securities	—			—			—			2.7			(1.4		)	1.3
	Other comprehensive income (loss)	$	(149.9	)	$	13.8		$	(136.1	)	$	39		$	(1.9	)	$	37.1
		Six Months Ended November 30, 2014									Six Months Ended November 30, 2013
	(in millions)	Before Tax			Tax			Net of Tax			Before Tax			Tax			Net of Tax
	Unrecognized actuarial gains (losses)	$	2.7		$	(0.8	)	$	1.9		$	—		$	—		$	—
	Foreign currency translation adjustments	(203.8		)	18.3			(185.5		)	18.2			13.5			31.7
	Unrealized gain (loss) on interest rate swaps	(5.7		)	4.3			(1.4		)	(9.4		)	9.3			(0.1		)
	Reclassifications on interest rate swaps	7.3			(2.7		)	4.6			36.1			(13.7		)	22.4
	Unrealized gain (loss) on available-for-sale securities	0.1			—			0.1			2.7			(1.4		)	1.3
	Other comprehensive income (loss)	$	(199.4	)	$	19.1		$	(180.3	)	$	47.6		$	7.7		$	55.3

Sharebased_Compensation_and_St

Share-based Compensation and Stock Plans	6 Months Ended
	Nov. 30, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Share-based Compensation and Stock Plans	Share-based Compensation and Stock Plans.
	The Company expenses all share-based payments to employees and non-employee distributors, including stock options, leveraged share awards and restricted stock units (“RSUs”), based on the grant date fair value over the required award service period using the graded vesting attribution method. As the Company’s common stock is not currently traded on a national securities exchange, the fair market value of the Company’s common shares is determined by the Compensation Committee. For awards with a performance vesting condition, the Company recognizes expense when the performance condition is considered probable to occur. Share-based compensation expense recognized was $4.8 million and $4.5 million for the three months ended November 30, 2014 and 2013, respectively, and $8.4 million and $9.2 million for the six months ended November 30, 2014 and 2013, respectively.
	On March 27, 2013, the Compensation Committee of LVB approved and adopted an Amended LVB Acquisition, Inc. 2012 Restricted Stock Unit Plan. The amendment permits certain participants in the Plan to be eligible to elect to receive a cash award with respect to their vested time-based RSUs subject to certain conditions, including the satisfaction of certain Company performance thresholds with respect to Adjusted EBITDA and unlevered free cash flow. To the extent the Company performance conditions have been satisfied for the applicable fiscal year, eligible participants will be entitled to elect to receive a cash award based on the fair market value of the Parent’s common stock on the first day of the applicable election period, payable in three installments over a two-year period, with respect to their vested time-based RSUs and such vested time-based RSU will be forfeited upon such election. Payment of the cash award is subject to the participants’ continued employment through the payment date (other than with respect to a termination by the Company without cause).

Income_Taxes

Income Taxes	6 Months Ended
	Nov. 30, 2014
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes.
	The Company applies guidance issued by the Financial Accounting Standards Board for uncertainty in income taxes. The Company records the liability for unrecognized tax positions as a long-term liability.
	The Company conducts business globally and, as a result, certain of its subsidiaries file income tax returns in the U.S. federal jurisdiction, and various state and foreign jurisdictions. In the normal course of business, the Company is subject to examinations by taxing authorities throughout the world, including major jurisdictions such as Australia, Canada, China, France, Germany, Japan, Luxembourg, the Netherlands, Spain, the United Kingdom and the United States. In addition, certain state and foreign tax returns are under examination by various regulatory authorities. The Company is no longer subject to U.S. federal income tax examinations for the fiscal years prior to and including the year ended May 31, 2010.
	The Company regularly reviews issues that are raised from ongoing examinations and open tax years to evaluate the adequacy of its liabilities. As the various taxing authorities continue with their audit/examination programs, the Company will adjust its reserves accordingly to reflect these settlements. As of November 30, 2014, the Company does not anticipate a significant change in its worldwide gross liabilities for unrecognized tax benefits within the succeeding twelve months.
	The Company’s effective income tax rate was 3.6% and 2.7% for the three and six months ended November 30, 2014, compared to (16.7)% and (233.3)% for the three and six months ended November 30, 2013. Primary factors in determining the effective tax rates include the mix of various jurisdictions in which profits are projected to be earned and taxed, as well as assertions regarding the expected repatriation of earnings of the Company’s foreign operations. Fluctuations in effective tax rates between comparable periods also reflect the discrete tax benefit or expense of items in continuing operations that represent tax effects not attributable to current-year ordinary income. Discrete items, consisting primarily of changes in deferred taxes due to state and international reorganizations, release of valuation allowance on state net operating loss carryforwards and the prospective reduction of the United Kingdom statutory corporate tax rate enacted in July 2013, decreased the quarterly income tax provision by ($26.1) million, or (242.1)%, in the six months ended November 30, 2013.

Segment_Reporting

Segment Reporting	6 Months Ended
	Nov. 30, 2014
Segment Reporting [Abstract]
Segment Reporting	Segment Reporting.
	The Company operates in one reportable segment, musculoskeletal products, which includes the designing, manufacturing and marketing of knees; hips; sports, extremities and trauma (“S.E.T.”); spine, bone healing and microfixation; dental; and cement, biologics and other products. Other products consist primarily of general instruments and operating room supplies. The Company operates in various geographies. These geographic markets are comprised of the United States, Europe and International. Major markets included in the International geographic market are Canada, Latin America and the Asia Pacific region.
	Net sales by product category for the three and six months ended November 30, 2014 and 2013 were as follows:
		Three Months Ended				Six Months Ended
	(in millions)	November 30, 2014		30-Nov-13		30-Nov-14		30-Nov-13
	Net sales by product:
	Knees	$	264.3	$	264	$	499	$	489.1
	Hips	168		167.7		323.3		317.4
	S.E.T.	160.6		160.3		315.1		309.8
	Spine, Bone Healing and Microfixation	124.5		104.9		247.3		206.5
	Dental	67.6		70.5		121.3		124.4
	Cement, Biologics and Other	58.6		58.3		112.4		109.2
	Total	$	843.6	$	825.7	$	1,618.40	$	1,556.40
	Net sales by geography for the three and six months ended November 30, 2014 and 2013 were as follows:
		Three Months Ended				Six Months Ended
	(in millions)	November 30, 2014		30-Nov-13		30-Nov-14		30-Nov-13
	Net sales by geography:
	United States	$	512.4	$	493.1	$	1,007.50	$	963
	Europe	206.1		211.8		367.4		363.3
	International(1)	125.1		120.8		243.5		230.1
	Total	$	843.6	$	825.7	$	1,618.40	$	1,556.40
	-1	International primarily includes Canada, Latin America and the Asia Pacific region.
	Long-term assets by geography as of November 30, 2014, May 31, 2014 and 2013 were as follows:
	(in millions)	30-Nov-14		May 31, 2014		May 31, 2013
	Long-term assets(1) by geography:
	United States	$	419.3	$	396.9	$	336.8
	Europe	173.4		241.4		255.7
	International	127.3		77.7		72.7
	Total	$	720	$	716	$	665.2
	-1	Defined as property, plant and equipment.

Guarantor_and_NonGuarantor_Fin

Guarantor and Non-Guarantor Financial Statements	6 Months Ended
	Nov. 30, 2014
Text Block [Abstract]
Guarantor and Non-Guarantor Financial Statements	Guarantor and Non-Guarantor Financial Statements.
	Each of Biomet’s existing wholly owned domestic subsidiaries fully, unconditionally, jointly, and severally guarantee the senior notes on a senior unsecured basis and the senior subordinated notes on a senior subordinated unsecured basis, in each case to the extent such subsidiaries guarantee Biomet’s senior secured cash flow facilities. LVB is neither an issuer nor guarantor of the notes described in Note 7.
	The following financial information presents the composition of the combined guarantor subsidiaries:
	CONDENSED CONSOLIDATING BALANCE SHEETS
		30-Nov-14
	(in millions)	Biomet, Inc.			Guarantors			Non-Guarantors			Eliminations			Total
	Assets
	Current assets:
	Cash and cash equivalents	$	—		$	88.1		$	188.4		$	—		$	276.5
	Accounts receivable, net	—			290.3			275			—			565.3
	Inventories, net	—			404.9			316.8			—			721.7
	Deferred income taxes	—			118.2			28.8			—			147
	Prepaid expenses and other	—			135.9			51.8			—			187.7
	Total current assets	—			1,037.40			860.8			—			1,898.20
	Property, plant and equipment, net	—			430.8			289.2			—			720
	Investments	—			12.9			0.6			—			13.5
	Investment in subsidiaries	7,799.20			—			—			(7,799.2		)	—
	Intangible assets, net	—			2,610.80			607.8			—			3,218.60
	Goodwill	—			3,143.50			433.6			—			3,577.10
	Other assets	—			119.9			10.8			—			130.7
	Total assets	$	7,799.20		$	7,355.30		$	2,202.80		$	(7,799.2	)	$	9,558.10
	Liabilities & Shareholder’s Equity
	Current liabilities:
	Current portion of long-term debt	$	132.8		$	—		$	—		$	—		$	132.8
	Accounts payable	—			60.5			41.6			—			102.1
	Accrued interest	50.6			—			0.1			—			50.7
	Accrued wages and commissions	—			67.3			56.1			—			123.4
	Other accrued expenses	—			282.7			70.9			—			353.6
	Total current liabilities	183.4			410.5			168.7			—			762.6
	Long-term debt	5,581.90			—			—			—			5,581.90
	Deferred income taxes	—			765.9			154.4			—			920.3
	Other long-term liabilities	—			172.8			86.6			—			259.4
	Total liabilities	5,765.30			1,349.20			409.7			—			7,524.20
	Shareholder’s equity	2,033.90			6,006.10			1,793.10			(7,799.2		)	2,033.90
	Total liabilities and shareholder’s equity	$	7,799.20		$	7,355.30		$	2,202.80		$	(7,799.2	)	$	9,558.10
		May 31, 2014
	(in millions)	Biomet, Inc.			Guarantors			Non-Guarantors			Eliminations			Total
	Assets
	Current assets:
	Cash and cash equivalents	$	—		$	101.8		$	145.8		$	—		$	247.6
	Accounts receivable, net	—			284.6			292.7			—			577.3
	Inventories	—			374.3			319.1			—			693.4
	Deferred income taxes	—			117.9			32			—			149.9
	Prepaid expenses and other	—			128			74.9			—			202.9
	Total current assets	—			1,006.60			864.5			—			1,871.10
	Property, plant and equipment, net	—			412.4			303.6			—			716
	Investments	—			11.9			0.6			—			12.5
	Investment in subsidiaries	7,882.90			—			—			(7,882.9		)	—
	Intangible assets, net	—			2,740.10			699.5			—			3,439.60
	Goodwill	—			3,146.70			487.7			—			3,634.40
	Other assets	—			81.5			11.5			—			93
	Total assets	$	7,882.90		$	7,399.20		$	2,367.40		$	(7,882.9	)	$	9,766.60
	Liabilities & Shareholder’s Equity
	Current liabilities:
	Current portion of long-term debt	$	133.1		$	—		$	—		$	—		$	133.1
	Accounts payable	—			86.9			48.4			—			135.3
	Accrued interest	53.3			—			0.1			—			53.4
	Accrued wages and commissions	—			90			78.7			—			168.7
	Other accrued expenses	—			259.4			95.3			—			354.7
	Total current liabilities	186.4			436.3			222.5			—			845.2
	Long-term debt	5,587.30			—			—			—			5,587.30
	Deferred income taxes	—			811.3			157.3			—			968.6
	Other long-term liabilities	—			170.8			85.5			—			256.3
	Total liabilities	5,773.70			1,418.40			465.3			—			7,657.40
Shareholder’s equity	2,109.20			5,980.80			1,902.10			(7,882.9		)	2,109.20
Total liabilities and shareholder’s equity	$	7,882.90		$	7,399.20		$	2,367.40		$	(7,882.9	)	$	9,766.60
CONDENSED CONSOLIDATING STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS)
	Three Months Ended November 30, 2014
(in millions)	Biomet, Inc.			Guarantors			Non-Guarantors			Eliminations			Total
Net sales	$	—		$	532.5		$	311.1		$	—		$	843.6
Cost of sales	—			158.5			25.3			—			183.8
Gross profit	—			374			285.8			—			659.8
Selling, general and administrative expense	—			238.5			129.2			—			367.7
Research and development expense	—			32			10.9			—			42.9
Amortization	—			60.6			19			—			79.6
Operating income	—			42.9			126.7			—			169.6
Interest expense	78.5			—			—			—			78.5
Other (income) expense	—			5.9			(8.0		)	—			(2.1		)
Income (loss) before income taxes	(78.5		)	37			134.7			—			93.2
Tax expense (benefit)	(29.8		)	14			19.2			—			3.4
Equity in earnings of subsidiaries	138.5			—			—			(138.5		)	—
Net income (loss)	$	89.8		$	23		$	115.5		$	(138.5	)	$	89.8
Other comprehensive income (loss)	$	(136.1	)	$	—		$	(135.7	)	$	135.7		$	(136.1	)
Total comprehensive income (loss)	$	(46.3	)	$	23		$	(20.2	)	$	(2.8	)	$	(46.3	)
	Three Months Ended November 30, 2013
(in millions)	Biomet, Inc.			Guarantors			Non-Guarantors			Eliminations			Total
Net sales	$	—		$	510.6		$	315.1		$	—		$	825.7
Cost of sales	—			221.5			33.6			—			255.1
Gross profit	—			289.1			281.5			—			570.6
Selling, general and administrative expense	—			209.6			130.8			—			340.4
Research and development expense	—			30.3			11.1			—			41.4
Amortization	—			61.8			13.4			—			75.2
Operating income (loss)	—			(12.6		)	126.2			—			113.6
Interest expense	106.1			—			(0.4		)	—			105.7
Other (income) expense	4.8			(1.2		)	0.1			—			3.7
Income (loss) before income taxes	(110.9		)	(11.4		)	126.5			—			4.2
Tax expense (benefit)	(42.1		)	(4.3		)	45.7			—			(0.7		)
Equity in earnings of subsidiaries	73.7			—			—			(73.7		)	—
Net income (loss)	$	4.9		$	(7.1	)	$	80.8		$	(73.7	)	$	4.9
Other comprehensive income (loss)	$	8.8		$	—		$	28.3		$	—		$	37.1
Total comprehensive income (loss)	$	13.7		$	(7.1	)	$	109.1		$	(73.7	)	$	42
	Six Months Ended November 30, 2014
(in millions)	Biomet, Inc.			Guarantors			Non-Guarantors			Eliminations			Total
Net sales	$	—		$	1,041.30		$	577.1		$	—		$	1,618.40
Cost of sales	—			364.7			35			—			399.7
Gross profit	—			676.6			542.1			—			1,218.70
Selling, general and administrative expense	—			469.7			259.7			—			729.4
Research and development expense	—			63.4			22.3			—			85.7
Amortization	—			116.1			35.4			—			151.5
Operating income	—			27.4			224.7			—			252.1
Interest expense	158.6			—			—			—			158.6
Other (income) expense	—			11.1			(17.4		)	—			(6.3		)
Income (loss) before income taxes	(158.6		)	16.3			242.1			—			99.8
Tax expense (benefit)	(60.3		)	6.1			56.9			—			2.7
Equity in earnings of subsidiaries	195.4			—			—			(195.4		)	—
Net income (loss)	$	97.1		$	10.2		$	185.2		$	(195.4	)	$	97.1
Other comprehensive income (loss)	$	(180.3	)	$	0.1		$	(183.6	)	$	183.5		$	(180.3	)
Total comprehensive income (loss)	$	(83.2	)	$	10.3		$	1.6		$	(11.9	)	$	(83.2	)
	Six Months Ended November 30, 2013
(in millions)	Biomet, Inc.			Guarantors			Non-Guarantors			Eliminations			Total
Net sales	$	—		$	992		$	564.4		$	—		$	1,556.40
Cost of sales	—			402.2			60.9			—			463.1
Gross profit	—			589.8			503.5			—			1,093.30
Selling, general and administrative expense	—			403.5			250.2			—			653.7
Research and development expense	—			58.2			20.7			—			78.9
Amortization	—			123.1			27.6			—			150.7
Operating income (loss)	—			5			205			—			210
Interest expense	193.1			—			0.2			—			193.3
Other (income) expense	4.8			(3.5		)	4.6			—			5.9
Income (loss) before income taxes	(197.9		)	8.5			200.2			—			10.8
Tax expense (benefit)	(75.2		)	3.3			46.7			—			(25.2		)
Equity in earnings of subsidiaries	158.7			—			—			(158.7		)	—
Net income (loss)	$	36		$	5.2		$	153.5		$	(158.7	)	$	36
Other comprehensive income (loss)	$	22.3		$	—		$	33		$	—		$	55.3
Total comprehensive income (loss)	$	58.3		$	5.2		$	186.5		$	(158.7	)	$	91.3
CONDENSED CONSOLIDATING STATEMENTS OF CASH FLOW
	Six Months Ended November 30, 2014
(in millions)	Biomet, Inc.			Guarantor			Non-Guarantors			Eliminations			Total
Cash flows provided by (used in) operating activities	$	3		$	60.9		$	98.8		$	—		$	162.7
Proceeds from sales/maturities of investments	—			—			15.2			—			15.2
Purchases of investments	—			—			(16.3		)	—			(16.3		)
Capital expenditures	—			(74.3		)	(57.8		)	—			(132.1		)
Other	—			(0.6		)	—			—			(0.6		)
Cash flows provided by (used in) investing activities	—			(74.9		)	(58.9		)	—			(133.8		)
Proceeds under revolvers	205			—			—			—			205
Payments under revolver	(20.0		)	—			—			—			(20.0		)
Retirement of term loans	(180.0		)	—			—			—			(180.0		)
Other	(8.0		)	0.3			—			—			(7.7		)
Cash flows provided by (used in) financing activities	(3.0		)	0.3			—			—			(2.7		)
Effect of exchange rate changes on cash	—			—			2.7			—			2.7
Increase (decrease) in cash and cash equivalents	—			(13.7		)	42.6			—			28.9
Cash and cash equivalents, beginning of period	—			101.8			145.8			—			247.6
Cash and cash equivalents, end of period	$	—		$	88.1		$	188.4		$	—		$	276.5
	Six Months Ended November 30, 2013
(in millions)	Biomet, Inc.			Guarantor			Non-Guarantors			Eliminations			Total
Cash flows provided by (used in) operating activities	$	96.5		$	278.5		$	(204.1	)	$	—		$	170.9
Proceeds from sales/maturities of investments	—			19			—						19
Purchases of investments	—			(19.6		)	—						(19.6		)
Capital expenditures	—			(53.9		)	(44.6		)	—			(98.5		)
Acquisitions, net of cash acquired - 2013 Spine Acquisition	—			(148.8		)	—			—			(148.8		)
Other	—			(0.8		)	0.1			—			(0.7		)
Cash flows provided by (used in) investing activities	—			(204.1		)	(44.5		)	—			(248.6		)
Payments under senior secured credit facilities	(14.9		)	—			—			—			(14.9		)
Proceeds under revolvers	155			—			4.3			—			159.3
Proceeds from senior notes due 2020 and term loans	870.5			—			—			—			870.5
Retirement of term loans	(1,091.6		)	—			—			—			(1,091.6		)
Payment of fees related to refinancing activities	(15.5		)	—			—			—			(15.5		)
Other	—			0.3			(9.3		)	—			(9.0		)
Cash flows provided by (used in) financing activities	(96.5		)	0.3			(5.0		)	—			(101.2		)
Effect of exchange rate changes on cash	—			—			(0.5		)	—			(0.5		)
Decrease in cash and cash equivalents	—			74.7			(254.1		)	—			(179.4		)
Cash and cash equivalents, beginning of period	—			35.3			320.3			—			355.6
Cash and cash equivalents, end of period	$	—		$	110		$	66.2		$	—		$	176.2

Restructuring

Restructuring	6 Months Ended
	Nov. 30, 2014
Restructuring and Related Activities [Abstract]
Restructuring	Restructuring.
	The Company recorded $3.2 million and $5.9 million in short-term restructuring costs during the three months ended November 30, 2014 and 2013, respectively, and $5.0 million and $12.2 million during the six months ended November 30, 2014 and 2013, respectively. During fiscal year 2014 the expense is employee severance costs, with fiscal year 2015 including both employee severance costs and plant closure costs. The expense resulted primarily from the planned closures of the Swindon, United Kingdom manufacturing facility and the Le Locle, Switzerland manufacturing facility. These restructuring charges were recorded within cost of sales, selling, general and administrative expense, and research and development expense and other accrued expenses. A summary of the severance and benefit costs in the periods presented is as follows:
	(in millions)	Restructuring Costs
	Restructuring Accrual:
	Balance at May 31, 2014	$	42.5
	Costs incurred and charged to expense	1.8
	Costs paid or otherwise settled	(21.0		)
	Non-cash adjustments(1)	(0.2		)
	Balance at August 31, 2014	23.1
	Costs incurred and charged to expense	3.2
	Costs paid or otherwise settled	(2.5		)
	Non-cash adjustments(1)	—
	Balance at November 30, 2014	$	23.8
	-1	Primarily related to foreign currency fluctuations.
	(in millions)	Restructuring Costs
	Restructuring Accrual:
	Balance at May 31, 2013	$	8.9
	Costs incurred and charged to expense	6.3
	Costs paid or otherwise settled	(5.3		)
	Non-cash adjustments(1)	0.7
	Balance at August 31, 2013	10.6
	Costs incurred and charged to expense	5.9
	Costs paid or otherwise settled	(3.9		)
	Non-cash adjustments(1)	0.8
	Balance at November 30, 2013	$	13.4
	-1	Primarily related to foreign currency fluctuations.

Contingencies

Contingencies	6 Months Ended
	Nov. 30, 2014
Commitments and Contingencies Disclosure [Abstract]
Contingencies	Contingencies.
	The Company is involved in various proceedings, legal actions and claims arising in the normal course of business, including proceedings related to product liability, governmental investigations, intellectual property, commercial litigation and other matters. The outcomes of these matters will generally not be known for an extended period of time. In certain of the legal proceedings, the claimants seek damages, as well as other compensatory relief, which could result in the payment of significant claims and settlements. For legal matters for which management has sufficient information to reasonably estimate the Company’s future obligations, a liability representing management’s best estimate of the probable cost, or the minimum of the range of probable losses when a best estimate within the range is not known, for the resolution of these legal matters is recorded. The estimates are based on consultation with legal counsel, previous settlement experience and settlement strategies. The Company’s accrual for contingencies, except for claims associated with metal-on-metal hip products, was $33.1 million and $39.1 million at November 30, 2014 and May 31, 2014, respectively, and primarily relate to certain product liability claims described below.
	Other than the claims associated with metal-on-metal hips and certain product liability claims, for which the estimated loss is included in the accrual amounts disclosed within this footnote, the relatively early stages of the other governmental investigations and other claims described below, and the complexities involved in these matters, the Company is unable to estimate a possible loss or range of possible loss for such matters until the Company knows, among other factors, (i) what claims, if any will survive dispositive motion practice, (ii) the extent of the claims, including the size of any potential class, particularly when damages are not specified or are indeterminate, (iii) how the discovery process will affect the litigation, (iv) the settlement posture of the other parties to the litigation and (v) any other factors that may have a material effect on the litigation.
	U.S. Department of Justice EBI Products Investigations and Other Matters
	In June 2013, Biomet received a subpoena from the U.S. Attorney’s Office for the District of New Jersey requesting various documents relating to the fitting of custom-fabricated or custom-fitted orthoses, or bracing, to patients in New Jersey, Texas and Washington. The Company has produced responsive documents and is fully cooperating with the request of the U.S. Attorney’s Office. The Company can make no assurances as to the time or resources that will be needed to devote to this inquiry or its final outcome.
	In February 2010, Biomet received a subpoena from the Office of the Inspector General of the U.S. Department of Health and Human Services requesting various documents relating to agreements or arrangements between physicians and the Company’s Interpore Cross subsidiary for the period from 1999 through the present and the marketing and sales activities associated with Interpore Cross’s spinal products. Biomet is cooperating with the request of the Office of the Inspector General. The Company can make no assurances as to the time or resources that will be needed to devote to this inquiry or its final outcome.
	In April 2009, Biomet received an administrative subpoena from the U.S. Attorney’s Office for the District of Massachusetts requesting various documents relating primarily to the Medicare reimbursement of and certain business practices related to the Company’s EBI subsidiary’s non-invasive bone growth stimulators. It is the Company’s understanding that competitors in the non-invasive bone growth stimulation market received similar subpoenas. The Company received subsequent subpoenas in connection with the investigation in September 2009, June 2010, February 2011 and March 2012, along with several informal requests for information. Biomet has produced responsive documents and is fully cooperating in the investigation. Biomet entered into a civil settlement agreement with the federal government on June 27, 2014 that resolved this matter.
	In April 2009, the Company became aware of a qui tam complaint alleging violations of the federal and various state False Claims Acts filed in the U.S. District Court for the District of Massachusetts, where it is currently pending. Biomet, Parent, and several of the Company’s competitors in the non-invasive bone growth stimulation market were named as defendants in this action. The allegations in the complaint are similar in nature to certain categories of requested documents in the above-referenced administrative subpoenas. The U.S. government has not intervened in the action. The Company is vigorously defending this matter and intends to continue to do so. The Company can make no assurances as to the time or resources that will be needed to devote to this investigation or its final outcome.
	U.S. Department of Justice Civil Division Investigation
	In September 2010, Biomet received a Civil Investigative Demand (“CID”) issued by the U.S. Department of Justice—Civil Division pursuant to the False Claims Act. The CID requests that the Company provide documents and testimony related to allegations that Biomet, OtisMed Corporation and Stryker Corp. have violated the False Claims Act relating to the marketing of, and payment submissions for, OtisMed’s OtisKnee (a trademark of OtisMed Corporation) knee replacement system.
	On December 8, 2014, the United States District Court for the District of New Jersey issued its Notice of Election to Decline to Intervene against Biomet and Biomet Orthopedics, LLC in U.S. v. Otismed Corp. The Notice indicates that the United States and the relator intend to file a Joint Stipulation of Dismissal as to the Biomet entities and the United States intends to dismiss these defendants without prejudice while the relator intends to dismiss the entities with prejudice.
	U.S. Securities and Exchange Commission Investigation
	On September 25, 2007, the Company received a letter from the SEC informing the Company that it was conducting an informal investigation regarding possible violations of the Foreign Corrupt Practices Act, or FCPA, in the marketing and sale of medical devices in certain foreign countries by companies in the medical devices industry. The FCPA prohibits domestic concerns, including U.S. companies and their officers, directors, employees, shareholders acting on their behalf and agents, from offering, promising, authorizing or making payments to foreign officials for the purpose of obtaining or retaining business abroad or otherwise obtaining an improper advantage. This law also requires issuers of publicly registered securities to maintain records which fairly and accurately reflect transactions and to maintain an adequate system of internal controls. In many countries, hospitals and clinics are government-owned and, therefore, healthcare professionals employed by such hospitals and clinics, with whom the Company regularly interacts, may meet the definition of a foreign official for purposes of the FCPA. On November 9, 2007, the Company received a letter from the DOJ requesting that any information provided to the SEC also be provided to the DOJ on a voluntary basis.
	On March 26, 2012, the Company resolved the DOJ’s and SEC’s investigations by entering into a Deferred Prosecution Agreement, referred to as a “DPA” in this consent solicitation statement/prospectus, with the DOJ and a Consent to Final Judgment, referred to as the “Consent” in this consent solicitation statement/prospectus, with the SEC. Pursuant to the DPA, the DOJ agreed to defer prosecution of the Company in connection with this matter, provided that the Company satisfies its obligations under the agreement over the term of the DPA. The DPA has a three-year term but provides that it may be extended in the sole discretion of the DOJ for an additional year. The DOJ further agreed to not continue its prosecution and to seek to dismiss its indictment should Biomet satisfy its obligations under the agreement over the term of the DPA.
	In addition, pursuant to the terms of the DPA, an independent external compliance monitor was appointed to review the Company’s compliance with the DPA, particularly in relation to the Company’s international sales practices, for at least the first 18 months of the term of the DPA. The monitor has divided his review into two phases. The first phase consisted of the monitor familiarizing himself with the Company’s global compliance program, assessing the effectiveness of the program and making recommendations for enhancement of the Company’s compliance program based on that review. The second phase commenced in June 2013 and consists of the monitor testing implementation of his recommended enhancements to the Company’s compliance program. The monitor recently identified that certain of the Company’s compliance enhancements have been implemented too recently to be satisfactorily tested, and the Company continues to work with the monitor to allow for such transactional testing. The Consent the Company entered into with the SEC mirrors the DPA’s provisions with respect to the compliance monitor. Compliance with the DPA requires substantial cooperation of the Company’s employees, distributors and sales agents and the healthcare professionals with whom they interact. These efforts not only involve expense, but also require management and other key employees to focus extensively on these matters.
	The Company agreed to pay a monetary penalty of $17.3 million to resolve the charges brought by the DOJ. The terms of the DPA and the associated monetary penalty reflect Biomet’s full cooperation throughout the investigation. The Company further agreed in its Consent to disgorge profits and pay prejudgment interest in the aggregate amount of $5.6 million.
	In October 2013, the Company became aware of certain alleged improprieties regarding its operations in Brazil and Mexico. The Company retained counsel and other experts to investigate both matters. Based on the results of its ongoing investigations, the Company has terminated, suspended or otherwise disciplined certain of the employees and executives involved in these matters, and has taken certain other remedial measures. Additionally, pursuant to the terms of the DPA, in April 2014, May 2014, July 2014, October 2014, and again in November 2014, the Company discussed matters raised by the investigations with the independent compliance monitor, DOJ and SEC.
	On July 2, 2014, the SEC issued a subpoena to the Company requiring that the Company produce certain documents relating to such matters. Moreover, pursuant to the DPA, the DOJ has sole discretion to determine whether conduct by the Company constitutes a violation or breach of the DPA. If the DOJ determines that the conduct underlying these investigations constitutes a violation or breach of the DPA, the DOJ could, among other things, extend or revoke the DPA or prosecute the Company and/or the involved employees and executives. The Company continues to cooperate with the SEC and DOJ and expects that discussions with the SEC and the DOJ will continue.
	From time to time, the Company is, and may continue to be, the subject of additional investigations. If, as a result of the investigations described above or any additional investigations, the Company is found to have violated one or more applicable laws, the Company’s business, financial condition, results of operations and cash flows could be materially adversely affected. If some of the Company’s existing business practices are challenged as unlawful, the Company may have to modify those practices, which could have a material adverse effect on the Company’s business, financial condition, results of operations and cash flows.
	Product Liability
	The Company has received claims for personal injury associated with its metal-on-metal hip products. The Company’s accrual for contingencies for claims associated with metal-on-metal hip products at November 30, 2014 and May 31, 2014 is $100.0 million and $123.5 million, respectively. The pre-trial management of certain of these claims has been consolidated in a multi-district proceeding in a federal court in South Bend, Indiana. Certain other claims are pending in various state courts. The Company believes the number of claims continues to increase incrementally due to the negative publicity regarding metal-on-metal hip products generally. The Company believes it has data that supports the efficacy and safety of its metal-on-metal hip products, and the Company intends to vigorously defend itself in these matters. The Company currently accounts for these claims in accordance with its standard product liability accrual methodology on a case by case basis. Given the substantial or indeterminate amounts sought in these matters, and the inherent unpredictability of such matters, an adverse outcome in these matters in excess of the amounts included in the Company’s accrual for contingencies could have a material adverse effect on the Company’s financial condition, results of operations and cash flows.
	The Company accrues anticipated costs of settlement, damages, and loss of product liability claims based on historical experience or to the extent specific losses are probable and estimable. If the estimate of a probable loss is in a range and no amount within the range is more likely, the Company accrues the minimum amount of the range. Such estimates and any subsequent changes in estimates may result in adjustments to the Company’s operating results in the future. The Company has self-insured reserves against product liability claims with insurance coverage above the retention limits. There are various other claims, lawsuits and disputes with third parties, investigations and pending actions involving various allegations against it. Product liability claims are routinely reviewed by the Company’s insurance carriers and management routinely reviews all claims for purposes of establishing ultimate loss estimates.
	As of December 31, 2014, the Company is a defendant in 2,033 product liability lawsuits relating to metal-on-metal hip implants. The majority of these cases involve the M2a-Magnum hip system. The cases are venued in various state and federal courts. 1,938 of the cases are currently consolidated in one federal multi-district proceeding in the U.S. District Court for the Northern District of Indiana. The Company has seen a decrease in the number of claims filed since the last date to participate in the settlement reached in the multi-district litigation involving the Company’s metal-on-metal hip systems expired in April 2014. To date, more than 479 metal-on-metal cases against the Company have been dismissed without prejudice.
	On February 3, 2014, the Company announced the settlement of the Multi-District Litigation entitled MDL 2,391 – In Re: Biomet M2a Magnum Hip Implant Product Liability Litigation. Lawsuits filed in the MDL by April 15, 2014 may participate in the settlement. The Company continues to evaluate the inventory of lawsuits in the MDL pursuant to the categories and procedures set forth in the settlement agreement. The final amount of payments under the settlement is uncertain. The settlement does not affect certain other claims relating to the Company’s metal-on-metal hip products that are pending in various state courts, or other claims that may be filed in the future.
	The Company paid $50.0 million and $25.0 million on September 26, 2014 and December 19, 2014, respectively, into a court ordered escrow account to fund certain payments of settlements set forth in the Settlement Agreement. The first of these payments exhausted the remainder of the self insured retention in the Company’s insurance program, which is $50.0 million. The Company is pursuing insurance claims for reimbursement for the amount in excess of the self insured retention. The Company maintains $100.0 million of third-party insurance coverage. The Company’s insurance carriers have been placed on notice of the claims associated with metal-on-metal hip products that are subject to the settlement and have been placed on notice of the terms of the settlement. As is customary in these situations, certain of the Company’s insurance carriers have reserved all rights under their respective policies. The Company continues to believe its contracts with the insurance carriers are enforceable for these claims and the settlement agreement. The Company continues to cooperate with its insurers’ requests in order to secure coverage for these claims. The Company has received a commitment from certain of its insurers to reimburse up to $75.0 million of expenses and settlement costs related to the metal-on-metal hip claims. During the three months ended November 30, 2014, the Company has received approximately $26.7 million in reimbursement from certain of its insurance carriers related to the metal-on-metal hip claims. The Company would be responsible for any amounts that its insurance carriers do not cover or for the amount by which ultimate losses exceed the amount of the Company’s third-party insurance coverage. As of November 30, 2014, a receivable of $48.3 million has been recorded. The Company is currently assessing any potential receivables to be recorded for additional recoveries from the insurance carriers.
	Future revisions in the Company’s estimates of these provisions could materially impact its results of operations and financial position. The Company uses the best information available to determine the level of accrued product liabilities, and the Company believes its accruals are adequate.
	Intellectual Property Litigation
	On May 3, 2013, Bonutti Skeletal Innovations LLC, a company formed to hold certain patents acquired from Dr. Peter M. Bonutti and an affiliate of patent licensing firm Acacia Research Group LLC, filed suit against us in the U.S. District Court for the Eastern District of Texas, alleging a failure to pay royalties due under a license agreement with Dr. Bonutti, misuse of confidential information and infringement of U.S. Patent Nos. 5,921,986; 6,099,531; 6,423,063; 6,638,279; 6,702,821; 7,070,557; 7,087,073; 7,104,996; 7,708,740; 7,806,896; 7,806,897; 7,828,852; 7,931,690; 8,133,229; and 8,147,514. Prior to the filing of this lawsuit, on March 8, 2013, the Company filed a complaint for declaratory judgment with the U.S. District Court for the Northern District of Indiana seeking a judgment of non-infringement and invalidity of the patents at issue, and Acacia Research Group LLC entered counterclaims of infringement seeking damages in an amount yet to be determined and injunctive relief. On September 17, 2013, the May 3, 2013 case filed in the Eastern District of Texas was dismissed. On March 31, 2014, the Company entered into a Settlement and License Agreement with Bonutti Skeletal Innovations LLC settling all claims related to U.S. Patents 5,921,986, 6,638,279, 7,070,557, 7,087,073, and 8,147,514 for a one-time payment, and on June 25, 2014, the U.S. District Court for the Northern District of Indiana issued an order dismissing the claims related to these patents with prejudice. The U.S. District Court for the Northern District of Indiana held a Markman hearing on September 24, 2014.  The Court has not yet ruled on the arguments presented.  The Company is vigorously defending this matter and believes that its defenses against infringement for the patents remaining in the suit are valid and meritorious. The Company can make no assurances as to the time or resources that will be needed to devote to this litigation or its final outcome.
	In December 2008, Heraeus Kulzer GmbH (“Heraeus”), initiated legal proceedings in Germany against Biomet, Biomet Europe BV and certain other subsidiaries of Biomet, alleging that Biomet and Biomet Europe BV misappropriated Heraeus trade secrets when developing Biomet Europe’s Refobacin and Biomet Bone Cement line of cements, which are referred to as European Cements. The lawsuit sought to preclude the defendants from producing, marketing and offering for sale their current line of European Cements and to compensate Heraeus for any damages incurred (alleged to be in excess of €30.0 million). On December 20, 2012, the trial court dismissed Biomet, Biomet Europe BV, Biomet Deutschland GmbH and other defendants from the lawsuit. Biomet Orthopaedics Switzerland GmbH was the only Biomet entity remaining as a defendant.
	Following an appeal by Heraeus (which, in the meantime, has assigned its claim to its affiliate Heraeus Medical GmbH-Heraeus and Heraeus Medical GmbH collectively referred to as “Heraeus” hereafter), on June 5, 2014, the German appeals court (i) enjoined Biomet, Biomet Europe BV and Biomet Deutschland GmbH from manufacturing, selling or offering the European Cements to the extent they contain certain raw materials in particular specifications; (ii) held the defendants jointly and severally liable to Heraeus for any damages from the sale of European Cements since 2005 and (iii) ruled that no further review may be sought. Damages have not been determined. The judgment is not final and the defendants will seek review (including review of the appeals court ruling that no further review may be sought) from Germany’s Supreme Court. The defendants issued a bank guaranty in favor of Heraeus for €11.25 million in order to stay the judgment. During the pendency of the stay, the defendants were entitled to continue the manufacture, marketing, sale and offering of European Cements in their current composition. On July 3, 2014, Heraeus offered counter security and which allowed Heraeus to terminate the stay and execute the judgment at any time. On August 21, 2014, Heraeus notified the Biomet Group that it would execute the judgment effective as of August 22, 2014. As a result, Biomet Europe BV and Biomet Deutschland GmbH are enjoined from the manufacture, marketing, sale and offering of European Cements in Germany. While Heraeus has indicated that it intends to take the position that the judgment would prohibit the manufacture, marketing, sale and offering of European Cements outside of Germany as well, Biomet, Biomet Europe BV and Biomet Deutschland GmbH will vigorously contest any attempt to extend the effect of the judgment beyond Germany. Biomet, Biomet Europe BV and Biomet Deutschland thus filed a declaratory action in Germany on August 3, 2014 to have the court determine the reach of the appeals court decision. On September 11, 2014 Heraeus filed a motion to have a penalty imposed on Biomet Deutschland and Biomet Europe BV based on continued sales of the European cements outside of Germany. Following a formal request by Biomet, on September 18, 2014, Heraeus returned Biomet’s portion of the bank guaranty to the extent it had been matched by Heraeus in July.
	No prediction can be made as to the likelihood of review being granted by Germany’s Supreme Court nor can any assurance be made as to the time or resources that will be needed to devote to this litigation or its final outcome.
	On September 8, 2014, Heraeus Medical GmbH (“Heraeus Medical”) filed a complaint against a Biomet supplier, Esschem, Inc. (“Esschem”) in the United States District Court for the Eastern District of Pennsylvania.   The lawsuit contains allegations that focus on two copolymer compounds that Esschem sells to Biomet which, in turn, incorporates the subject copolymers into certain bone cement products that compete with Heraeus’ bone cement products.  The complaint alleges that Biomet helped Esschem to develop these copolymers, using Heraeus trade secrets that Biomet allegedly misappropriated. The complaint asserts a claim under the Pennsylvania Trade Secrets Act, as well as other various common law tort claims-all based upon the same trade secret misappropriation theory.  Heraeus is seeking to enjoin Esschem from supplying the copolymers to any third party and actual damages in an unspecified amount.  The complaint also seeks punitive damages, costs, and attorneys’ fees. Other than the filing of the complaint, there has been no other activity in the case yet.  If Esschem is enjoined, Biomet may not be able to obtain the copolymers from another supplier and as a result may not be able to continue to manufacture the subject bone cement products. Although Heraeus has not named Biomet as a party to this lawsuit, Biomet has agreed, at Esschem’s request and subject to certain limitations, to indemnify Esschem for any liability, damages and legal costs related to this matter. On September 29, 2014, the Court held a hearing on Heraeus’s Motion for a Temporary Restraining Order. On November 3, 2014, the court entered an order denying Heraeus’s Motion for a Temporary Restraining Order.
	Other Matters
	There are various other claims, lawsuits, disputes with third parties, investigations and pending actions involving various allegations against the Company incident to the operation of its business, principally product liability and intellectual property cases. Each of these matters is subject to various uncertainties, and it is possible that some of these matters may be resolved unfavorably to the Company. The Company accrues for losses that are deemed to be probable and subject to reasonable estimate.
	Based on the advice of the Company’s counsel in these matters, the Company believes that it is unlikely that the resolution of any of these matters and any liabilities in excess of amounts provided will be material to the Company’s financial position, results of operations or cash flows.

Related_Parties

Related Parties	6 Months Ended
	Nov. 30, 2014
Related Party Transactions [Abstract]
Related Parties	Related Parties.
	Transactions with the Principal Stockholders
	On December 18, 2006, Biomet, Inc. entered into an Agreement and Plan of Merger with LVB Acquisition, LLC, a Delaware limited liability company , which was subsequently converted to a corporation, LVB Acquisition, Inc., and LVB Acquisition Merger Sub, Inc., an Indiana corporation and a wholly-owned subsidiary of Parent (“Purchaser”), which agreement was amended and restated as of June 7, 2007 and which we refer to as the “2007 Merger Agreement.” Pursuant to the 2007 Merger Agreement, on June 13, 2007, Purchaser commenced a cash tender offer (the “Offer”) to purchase all of Biomet, Inc.’s outstanding common shares, without par value (the “Shares”) at a price of $46.00 per Share (the “Offer Price”) without interest and less any required withholding taxes. The Offer was made pursuant to Purchaser’s offer to purchase dated June 13, 2007 and the related letter of transmittal, each of which was filed with the SEC on June 13, 2007. In connection with the Offer, Purchaser entered into a credit agreement dated as of July 11, 2007 for a $6,165.0 million senior secured term loan facility (the “Tender Facility”), maturing on June 6, 2008, and pursuant to which it borrowed approximately $4,181.0 million to finance a portion of the Offer and pay related fees and expenses. The Offer expired at midnight, New York City time, on July 11, 2007, with approximately 82% of the outstanding Shares having been tendered to Purchaser. At Biomet, Inc.’s special meeting of shareholders held on September 5, 2007, more than 91% of Biomet, Inc.’s shareholders voted to approve the proposed merger, and Parent acquired Biomet, Inc. on September 25, 2007 through a reverse subsidiary merger with Biomet, Inc. being the surviving company (the “2007 Merger”). Subsequent to the acquisition, Biomet, Inc. became a subsidiary of Parent. Approximately 97% of the outstanding shares of Parent common stock are owned by LVB Acquisition Holding, LLC, or “Holding”, an entity controlled collectively by a consortium of private equity funds affiliated with The Blackstone Group, Goldman, Sachs & Co., Kohlberg Kravis Roberts & Co., and TPG Global, LLC (each a “Principal Stockholder” and collectively, the “Principal Stockholders”), and certain investors who agreed to co-invest with the Principal Stockholders, or (the “Co-Investors”). These transactions, including the 2007 Merger and the Company’s payment of any fees and expenses related to these transactions, are referred to collectively as the “2007 Acquisition.”
	Management Services Agreement
	Upon completion of the 2007 Acquisition, Biomet entered into a management services agreement with certain affiliates of the Principal Stockholders, pursuant to which such affiliates of the Principal Stockholders or their successors assigns, affiliates, officers, employees, and/or representatives and third parties (collectively, the “Managers”) provide management, advisory, and consulting services to the Company. Pursuant to such agreement, the Managers received a transaction fee equal to 1% of total enterprise value of the 2007 Acquisition for the services rendered by such entities related to the 2007 Acquisition upon entering into the agreement, and the Principal Stockholders receive an annual monitoring fee equal to 1% of the Company’s annual Adjusted EBITDA (as defined in the credit agreement) as compensation for the services rendered and reimbursement for out-of-pocket expenses incurred by the Managers in connection with the agreement and the 2007 Acquisition. The Company is required to pay the Principal Stockholders the monitoring fee on a quarterly basis in arrears. The total amount of Principal Stockholder fees was $3.1 million and $3.0 million for the three months ended November 30, 2014 and 2013, respectively, and $5.7 million and $5.4 million for the six months ended November 30, 2014 and 2013, respectively. The management services agreement includes customary exculpation and indemnification provisions in favor of the Managers and their affiliates. The Company is also required by the management services agreement to pay certain subsequent fees for advice rendered in connection with financings or refinancings (equity or debt), acquisitions, dispositions, spin-offs, split-offs, dividends, recapitalizations, an initial underwritten public offering and change of control transactions involving the Company. Upon completion of the Zimmer Merger, which represents a change in control, the Company expects to pay a one-time fee to affiliates of its Principal Stockholders in the amount of $88.0 million.
	Amended and Restated Limited Liability Company Operating Agreement of LVB Holding
	On September 27, 2007, certain investment funds associated with or designated by the Principal Stockholders, or the Principal Stockholder Funds, entered into an amended and restated limited liability company operating agreement, or the “LLC Agreement,” in respect of LVB Holding. The LLC Agreement contains agreements among the parties with respect to the election of the Company’s directors and the directors of its parent companies, restrictions on the issuance or transfer of interests in the Company and other corporate governance provisions (including the right to approve various corporate actions).
	Pursuant to the LLC Agreement, each of the Principal Stockholders has the right to nominate, and has nominated, two directors to Biomet’s and LVB’s Board of Directors and also is entitled to appoint one non-voting observer to Biomet’s and LVB’s Board of Directors for so long as such Principal Stockholder remains a member of LVB Holding. In addition to their right to appoint non-voting observers to Biomet’s and LVB’s Board of Directors, certain of the Principal Stockholder Funds have certain other management rights to the extent that any such Principal Stockholder Fund is required to operate as a “venture capital operating company” as defined in the regulations issued by the U.S. Department of Labor at Section 2510.3-101 of Part 2510 of Chapter XXV, Title 29 of the Code of Federal Regulations, or any successor regulations. Each Principal Stockholder’s right to nominate directors is freely assignable to funds affiliated with such Principal Stockholder, and is assignable to non-affiliates of such Principal Stockholder only if the assigning Principal Stockholder transfers its entire interest in LVB Holding not previously transferred and only with the prior written consent of the Principal Stockholders holding at least 70% of the membership interests in LVB Holding, or “requisite Principal Stockholder consent”. In addition to their rights under the LLC Agreement, the Principal Stockholders may also appoint one or more persons unaffiliated with any of the Principal Stockholders to the Board of Directors. Following Purchaser’s purchase of the Shares tendered in the Offer, the Principal Stockholders jointly appointed Dane A. Miller, Ph.D. to the Board of Directors in addition to the two directors appointed by each of the Principal Stockholders. In addition, as provided under the LLC Agreement, Jeffrey R. Binder, the CEO of Biomet serves on Biomet’s and LVB’s Board of Directors.
	Pursuant to the LLC Agreement, each director has one vote for purposes of any Board of Directors action, and all decisions of the Board of Directors require the approval of a majority of the directors designated by the Principal Stockholders. In addition, the LLC Agreement provides that certain major decisions regarding the Company or its parent companies require the requisite Principal Stockholder consent.
	The LLC Agreement includes certain customary agreements with respect to restrictions on the issuance or transfer of interests in Biomet and LVB, including preemptive rights, tag-along rights and drag-along rights.
	The Co-Investors have also been admitted as members of LVB Holding, both directly and through Principal Stockholder-controlled investment vehicles. Although the Co-Investors are therefore parties to the LLC Agreement, they have no rights with respect to the election of Biomet’s or LVB’s directors or the approval of its corporate actions.
	The Principal Stockholders have also caused LVB Holding and Parent to enter into an agreement with the Company obligating the Company and Parent to take all actions necessary to give effect to the corporate governance, preemptive rights, transfer restriction and certain other provisions of the LLC Agreement, and prohibiting the Company and Parent from taking any actions that would be inconsistent with such provisions of the LLC Agreement.
	Registration Rights Agreement
	The Principal Stockholder Funds and the Co-Investors also entered into a registration rights agreement with Holding, LVB and Biomet upon the closing of the 2007 Acquisition. Pursuant to this agreement, the Principal Stockholder Funds have the power to cause Holding, LVB and Biomet to register their, the Co-Investors’ and certain other persons’ equity interests under the Securities Act and to maintain a shelf registration statement effective with respect to such interests. The agreement also entitles the Principal Stockholder Funds and the Co-Investors to participate in any future registration of equity interests under the Securities Act that LVB Holding, LVB or Biomet may undertake. Certain trusts associated with Dr. Dane A. Miller, Ph.D., one of our directors, are also parties to the registration rights agreement and benefit from its provisions.
	On August 8, 2012 and October 2, 2012, Goldman, Sachs & Co. and the other initial purchasers of the new senior notes and new senior subordinated notes entered into registration rights agreements with Biomet. Pursuant to these agreements, Biomet is obligated, for the sole benefit of Goldman, Sachs & Co. in connection with its market-making activities with respect to the new senior notes and new senior subordinated notes, to file a registration statement under the Securities Act in a form approved by Goldman, Sachs & Co. and to keep such registration statement continually effective for so long as Goldman, Sachs & Co. may be required to deliver a prospectus in connection with transactions in senior and senior subordinated notes due 2020 and to supplement or make amendments to such registration statement as when required by the rules and regulations applicable to such registration statement.
	Management Stockholders’ Agreements
	On September 13, 2007 and November 6, 2007, LVB Holding, LVB and the Principal Stockholder Funds entered into stockholders agreements with certain of the Company’s senior executives and other management stockholders. Pursuant to the terms of the LVB Acquisition, Inc. Management Equity Incentive Plan, LVB Acquisition, Inc. Restricted Stock Unit Plan and LVB Acquisition, Inc. 2012 Restricted Stock Unit Plan, participants who exercise their vested options or settle their vested restricted stock units are required to become parties to the agreement dated November 6, 2007. The stockholder agreements contain agreements among the parties with respect to restrictions on the transfer and issuance of shares, including preemptive, drag-along, tag-along, and call/put rights.
	Agreements with Dr. Dane A. Miller, Ph.D.
	On January 14, 2010, Biomet entered into a consulting agreement with Dr. Dane A. Miller Ph.D., pursuant to which it will pay Dr. Miller a consulting fee of $0.25 million per fiscal year for Dr. Miller’s consulting services and will reimburse Dr. Miller for out-of-pocket fees and expenses relating to an off-site office and administrative support in an amount of $0.1 million per year. The term of the agreement extends through the earlier of September 1, 2011, an initial public offering or a change of control. The agreement also contains certain restrictive covenants prohibiting Dr. Miller from competing with the Company and soliciting employees of the Company during the term of the agreement and for a period of one year following such term. On September 6, 2011, the Company entered into an amendment to the consulting agreement with Dr. Miller, pursuant to which it agreed to increase the expenses relating to an off-site office and administrative support from $0.1 million per year to $0.15 million per year and extend the term of the agreement through the earlier of September 1, 2013, an initial public offering or a change of control. On August 19, 2013, the Company entered into an amendment to the consulting agreement with Dr. Miller, pursuant to which it agreed to extend the term of the agreement through the earlier of September 1, 2014, an initial public offering or a change of control. On April 22, 2014, Biomet entered into a third amendment to the consulting agreement with Dr. Miller, pursuant to which it agreed to pay him, upon a termination of his consulting agreement, consulting fees owed to date and a termination fee of $2 million upon the earlier of a change in control or an initial public offering, provided such event occurs prior to January 1, 2016. Dr. Miller received payments under the consulting agreement of $0.1 million and $0.1 million during the three and six months ended November 30, 2014, respectively, $0.1 million during the six months ended November 30, 2013, with no payments during the three months ended November 30, 2013.
	In addition, on April 25, 2008, LVB Holding, LVB and two trusts associated with Dr. Miller, the Dane Miller Trust and the Mary Louise Miller Trust, entered into a stockholders agreement. Certain additional trusts associated with Dr. Miller have since become party to that stockholders agreement. The stockholder agreement contains agreements among the parties with respect to restriction on transfer of shares, including rights of first offer, drag-along and tag-along rights.
	Indemnification Priority Agreement
	On January 11, 2010, Biomet and LVB entered into an indemnification priority agreement with the Principal Stockholders (or certain affiliates designated by the Principal Stockholders) pursuant to which Biomet and LVB clarified certain matters regarding the existing indemnification and advancement of expenses rights provided by Biomet and LVB pursuant to their respective charters and the management services agreement described above. In particular, pursuant to the terms of the indemnification agreement, Biomet acknowledged that as among Biomet, LVB and the Principal Stockholders and their respective affiliates, the obligation to indemnify or advance expenses to any director appointed by any of the Principal Stockholders will be payable in the following priority: Biomet will be the primary source of indemnification and advancement; LVB will be the secondary source of indemnification and advancement; and any obligation of a Principal Stockholder-affiliated indemnitor to indemnify or advance expenses to such director will be tertiary to Biomet’s and, then, LVB obligations. In the event that either Biomet or LVB fails to indemnify or advance expenses to any such director in contravention of its obligations, and any Principal Stockholder-affiliated indemnitor makes any indemnification payment or advancement of expenses to such director on account of such unpaid liability, such Principal Stockholder-affiliated indemnitor will be subrogated to the rights of such director under any such Biomet or LVB indemnification agreement.
	Equity Healthcare
	Effective January 1, 2009, Biomet entered into an employer health program agreement with Equity Healthcare LLC (“Equity Healthcare”). Equity Healthcare negotiates with providers of standard administrative services for health benefit plans as well as other related services for cost discounts and quality of service monitoring capability by Equity Healthcare. Because of the combined purchasing power of its client participants, Equity Healthcare is able to negotiate pricing terms for providers that are believed to be more favorable than the companies could obtain for themselves on an individual basis.
	In consideration for Equity Healthcare’s provision of access to these favorable arrangements and its monitoring of the contracted third parties’ delivery of contracted services to the Company, the Company pays Equity Healthcare a fee of $2 per participating employee per month (“PEPM Fee”). As of November 30, 2014, the Company had approximately 3,200 employees enrolled in its health benefit plans in the United States.
	Equity Healthcare may also receive a fee (“Health Plan Fees”) from one or more of the health plans with whom Equity Healthcare has contractual arrangements if the total number of employees joining such health plans from participating companies exceeds specified thresholds. If and when Equity Healthcare reaches the point at which the aggregate of its receipts from the PEPM Fee and the Health Plan Fees have covered all of its allocated costs, it will apply the incremental revenues derived from all such fees to (a) reduce the PEPM Fee otherwise payable by the Company; (b) avoid or reduce an increase in the PEPM Fee that might otherwise have occurred on contract renewal; or (c) arrange for additional services to the Company at no cost or reduced cost.
	Equity Healthcare is an affiliate of Blackstone, with whom Timur Akazhanov and Chinh Chu, members of the Company’s Board of Directors, are affiliated and in which they may have an indirect pecuniary interest.
	There were payments of $0.1 million and $0.1 million for the three and six months ended November 30, 2013, respectively, with no payments made during the three or six months ended November 30, 2014.
	Core Trust Purchasing Group Participation Agreement
	Effective May 1, 2007, Biomet entered into a 5-year participation agreement (“Participation Agreement”) with Core Trust Purchasing Group, a division of HealthTrust Purchasing Corporation (“CPG”), designating CPG as the Company’s exclusive “group purchasing organization” for the purchase of certain products and services from third party vendors. Effective June 1, 2012, Biomet entered into an amendment to extend the term of the Participation Agreement with CPG. CPG secures from vendors pricing terms for goods and services that are believed to be more favorable than participants in the group purchasing organization could obtain for themselves on an individual basis. Under the participation agreement, the Company must purchase 80% of the requirements of its participating locations for core categories of specified products and services, from vendors participating in the group purchasing arrangement with CPG or CPG may terminate the contract. In connection with purchases by its participants (including the Company), CPG receives a commission from the vendors in respect of such purchases. The total amount of fees paid to CPG were $0.1 million and $0.2 million for the three months ended November 30, 2014 and 2013, respectively, and $0.1 million and $0.5 million for the six months ended November 30, 2014 and 2013, respectively.
	Although CPG is not affiliated with Blackstone, in consideration for Blackstone’s facilitating Biomet’s participation in CPG and monitoring the services CPG provides to the Company, CPG remits a portion of the commissions received from vendors in respect of the Company’s purchases under the Participation Agreement to an affiliate of Blackstone, with whom Timur Akazhanov and Chinh Chu, members of the Company’s Board of Directors, are affiliated and in which they may have an indirect pecuniary interest.
	Other
	Biomet currently holds interest rate swaps with Goldman Sachs. As part of this relationship, the Company receives information from Goldman Sachs that allows it to perform effectiveness testing on a monthly basis.
	Biomet may from time to time, depending upon market conditions, seek to purchase debt securities issued by Biomet or its subsidiaries in open market or privately negotiated transactions or by other means. Biomet understands that its indirect controlling stockholders may from time to time also seek to purchase debt securities issued by the Company or its subsidiaries in open market or privately negotiated transactions or by other means.
	Capital Contributions and Share Repurchases
	At the direction of LVB, Biomet may fund the repurchase of common shares of its parent company, from former employees pursuant to the LVB Acquisition, Inc. management Stockholders’ Agreement. There were no repurchases during the three or six months ended November 30, 2014 and 2013. There were no additional contributions for the three or six months ended November 30, 2014 and 2013.

Recent_Acquisitions_by_Biomet_

Recent Acquisitions by Biomet (Tables)	6 Months Ended
	Nov. 30, 2014
Business Combinations [Abstract]
Preliminary Purchase Price Allocation	The following table summarizes the purchase price allocation:
	(in millions)
	Cash	$	2
	Accounts receivable	16.5
	Inventory	24.8
	Prepaid expenses and other	11
	Instruments	9.9
	Other property, plant and equipment	2.1
	Deferred tax liability	(36.8		)
	Other liabilities assumed	(20.7		)
	Intangible assets	102.3
	Goodwill	39.7
	Purchase price	$	150.8
Pro Forma Information	The unaudited pro forma financial information for the combined entity is as follows:
		Three Months Ended			Six Months Ended
	(in millions)	30-Nov-13			November 30, 2013
	Net sales	$	841.5		$	1,595.30
	Net income	$	7.6		$	35.2

Inventories_Tables

Inventories (Tables)	6 Months Ended
	Nov. 30, 2014
Inventory Disclosure [Abstract]
Components of Inventories	Inventories consisted of the following:
	(in millions)	30-Nov-14		May 31, 2014
	Raw materials	$	91.3	$	83.1
	Work-in-process	48.2		54.4
	Finished goods	582.2		555.9
	Inventories	$	721.7	$	693.4

Property_Plant_and_Equipment_T

Property, Plant and Equipment (Tables)	6 Months Ended
	Nov. 30, 2014
Property, Plant and Equipment [Abstract]
Useful Lives of Property, Plant and Equipment	Useful lives by major product category consisted of the following:
		Useful life
	Land improvements	20 years
	Buildings and leasehold improvements	30 years
	Machinery and equipment	5-10 years
	Instruments	4 years
Components of Property, Plant and Equipment	Property, plant and equipment consisted of the following:
	(in millions)	30-Nov-14			May 31, 2014
	Land and land improvements	$	40.4		$	40.8
	Buildings and leasehold improvements	124.5			126.8
	Machinery and equipment	431.2			414.5
	Instruments	814.2			791.9
	Construction in progress	36.1			47.9
	Total property, plant and equipment	1,446.40			1,421.90
	Accumulated depreciation	(726.4		)	(705.9		)
	Total property, plant and equipment, net	$	720		$	716

Investments_Tables

Investments (Tables)	6 Months Ended
	Nov. 30, 2014
Investments, Debt and Equity Securities [Abstract]
Summary of Company's Investment Securities	At November 30, 2014, the Company’s investment securities were classified as follows:
		Amortized		Unrealized					Fair
	(in millions)	Cost		Gains		Losses			Value
	Available-for-sale:
	Equity securities	$	0.5	$	0.1	$	—		$	0.6
	Time deposit	10.2		—		(0.1		)	10.1
	Total available-for-sale investments	$	10.7	$	0.1	$	(0.1	)	$	10.7
		Amortized		Realized					Fair
		Cost		Gains		Losses			Value
	Trading:
	Equity securities	$	2.7	$	0.1	$	—		$	2.8
	Total trading investments	$	2.7	$	0.1	$	—		$	2.8
	At May 31, 2014, the Company’s investment securities were classified as follows:
		Amortized		Unrealized					Fair
	(in millions)	Cost		Gains		Losses			Value
	Available-for-sale:
	Equity securities	$	0.2	$	0.6	$	(0.3	)	$	0.5
	Time deposit	10.2		—		—			10.2
	Total available-for-sale investments	$	10.4	$	0.6	$	(0.3	)	$	10.7
		Amortized		Realized					Fair
		Cost		Gains		Losses			Value
	Trading:
	Equity securities	$	1.6	$	0.3	$	(0.1	)	$	1.8
	Total trading investments	$	1.6	$	0.3	$	(0.1	)	$	1.8

Goodwill_and_Other_Intangible_1

Goodwill and Other Intangible Assets (Tables)	6 Months Ended
	Nov. 30, 2014
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Intangible Assets	Intangible assets consisted of the following at November 30, 2014 and May 31, 2014:
	(in millions)	November 30, 2014
		Gross					Net
		Carrying		Accumulated			Carrying
		Amount		Amortization			Amount
	Core technology	$	1,748.90	$	(605.4	)	$	1,143.50
	Completed technology	662.7		(281.3		)	381.4
	Product trade names	188.8		(80.4		)	108.4
	Customer relationships	2,304.70		(1,021.1		)	1,283.60
	Non-compete contracts	4.9		(4.6		)	0.3
	Sub-total	4,910.00		(1,992.8		)	2,917.20
	Corporate trade names	301.4		—			301.4
	Total	$	5,211.40	$	(1,992.8	)	$	3,218.60
	(in millions)	May 31, 2014
		Gross					Net
		Carrying		Accumulated			Carrying
		Amount		Amortization			Amount
	Core technology	$	1,743.30	$	(569.8	)	$	1,173.50
	Completed technology	672		(262.1		)	409.9
	Product trade names	208.1		(77.6		)	130.5
	Customer relationships	2,371.60		(955.9		)	1,415.70
	Non-compete contracts	4.9		(4.6		)	0.3
	Sub-total	4,999.90		(1,870.0		)	3,129.90
	Corporate trade names	309.7		—			309.7
	Total	$	5,309.60	$	(1,870.0	)	$	3,439.60
Weighted Average Useful Life of Intangible Assets	The weighted average useful life of the intangibles at November 30, 2014 is as follows:
		Weighted Average
		Useful Life
	Core technology	14 years
	Completed technology	8 years
	Product trade names	12 years
	Customer relationships	13 years
	Non-compete contracts	1 year
	Corporate trade names	Indefinite life

Debt_Tables

Debt (Tables)	6 Months Ended
	Nov. 30, 2014
Debt Disclosure [Abstract]
Schedule of Terms and Carrying Value of Debt Instrument	The terms and carrying value of each debt instrument at November 30, 2014 and May 31, 2014 are set forth below:
	(U.S. dollars in millions)	Maturity Date	Interest Rate	Currency	30-Nov-14		May 31, 2014
	Debt Instruments
	Term loan facility B	March 25, 2015	LIBOR + 3.00%	USD	$	102.7	$	103.3
	Term loan facility B-1	July 25, 2017	LIBOR + 3.50%	USD	$	2,772.20	$	2,959.60
	Cash flow revolving credit facility	April 25, 2017	LIBOR + 3.50%	USD	$	—	$	—
	Cash flow revolving credit facility	April 25, 2017	LIBOR + 3.50%	USD/EUR	$	—	$	—
	Asset-based revolving credit facility	July 25, 2017	LIBOR + 2.00%	USD	$	185	$	—
	Senior notes	August 1, 2020	6.50%	USD	$	1,825.00	$	1,825.00
	Senior subordinated notes	October 1, 2020	6.50%	USD	$	800	$	800
	Premium on notes				$	29.8	$	32.5
	Total debt				$	5,714.70	$	5,720.40

Fair_Value_Measurements_Tables

Fair Value Measurements (Tables)	6 Months Ended
	Nov. 30, 2014
Fair Value Disclosures [Abstract]
Fair value of assets and liabilities measured on recurring basis	The following table provides information by level for assets and liabilities that are measured at fair value on a recurring basis at November 30, 2014 and May 31, 2014:
				Fair Value Measurements
		Fair Value at		Using Inputs Considered as
	(in millions)	November 30, 2014		Level 1		Level 2		Level 3
	Assets:
	Money market funds	$	124.6	$	124.6	$	—	$	—
	Time deposits	10.2		—		10.2		—
	Pension plan assets	144.9		—		129.9		15
	Foreign currency exchange contracts	6		—		6		—
	Equity securities	3.4		3.2		—		0.2
	Total assets	$	289.1	$	127.8	$	146.1	$	15.2
	Liabilities:
	Interest rate swaps	$	15.5	$	—	$	15.5	$	—
	Foreign currency exchange contracts	0.4		—		0.4		—
	Total liabilities	$	15.9	$	—	$	15.9	$	—
				Fair Value Measurements
		Fair Value at		Using Inputs Considered as
	(in millions)	May 31, 2014		Level 1		Level 2		Level 3
	Assets:
	Money market funds	$	145	$	145	$	—	$	—
	Time deposits	25.8		—		25.8		—
	Pension plan assets	147.5		—		132.5		15
	Foreign currency exchange contracts	1.1		—		1.1		—
	Equity securities	0.5		0.3		—		0.2
	Total assets	$	319.9	$	145.3	$	159.4	$	15.2
	Liabilities:
	Interest rate swaps	$	20.2	$	—	$	20.2	$	—
	Foreign currency exchange contracts	1.3		—		1.3		—
	Total liabilities	$	21.5	$	—	$	21.5	$	—

Derivative_Instruments_and_Hed1

Derivative Instruments and Hedging Activities (Tables)	6 Months Ended
	Nov. 30, 2014
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Schedule of Summary Existing Swap Agreements	The table below summarizes existing swap agreements at November 30, 2014 and May 31, 2014:
	(in millions)										Fair Value at				Fair Value at
				Notional							30-Nov-14				May 31, 2014
	Structure	Currency		Amount				Effective Date	Termination Date		Asset (Liability)				Asset (Liability)
	5 years	USD		$	195			September 25, 2009	September 25, 2014		$	—			$	(1.7	)
	2 years	USD		190				March 25, 2013	March 25, 2015		(0.4		)		(1.0		)
	3 years	USD		270				December 27, 2013	September 25, 2016		(4.7		)		(5.8		)
	5 years	USD		350				September 25, 2012	September 25, 2017		(5.3		)		(6.0		)
	5 years	USD		350				September 25, 2012	September 25, 2017		(5.3		)		(5.9		)
	Credit valuation adjustment										0.2				0.2
	Total interest rate instruments										$	(15.5	)		$	(20.2	)
Schedule of Interest Rate Swap	The tables below summarize the effective portion and ineffective portion of the Company’s interest rate swaps before tax for the three and six months ended November 30, 2014 and 2013:
	(in millions)	Three Months Ended							Six Months Ended
	Derivatives in cash flow hedging relationship	30-Nov-14				30-Nov-13			30-Nov-14				30-Nov-13
	Interest rate swaps:
	Amount of gain (loss) recognized in OCI	$	(0.6	)		$	4.5		$	4.7			$	26.2
	Amount of (gain) loss reclassified from accumulated OCI into interest expense (effective portion)	2.5				6.8			7.3				14.3
	Amount (gain) loss recognized in other income (expense) (ineffective portion and amount excluded from effectiveness testing)	—				21.8			—				21.8

Accumulated_Other_Comprehensiv1

Accumulated Other Comprehensive Income (Loss) (Tables)	6 Months Ended
	Nov. 30, 2014
Equity [Abstract]
Schedule of Accumulated Other Comprehensive Income (Loss)	Accumulated other comprehensive income (loss) and the related components, net of tax, are included in the table below:
	(in millions)	Unrecognized actuarial gains (losses)			Foreign currency translation adjustments			Unrealized gain (loss) on interest rate swaps			Unrealized gain (loss) on available-for-sale securities			Accumulated other comprehensive income (loss)
	31-May-14	$	(11.0	)	$	62.6		$	(12.3	)	$	—		$	39.3
	OCI before reclassifications	1.9			(185.5		)	(1.4		)	0.1			(184.9		)
	Reclassifications	—			—			4.6			—			4.6
	30-Nov-14	$	(9.1	)	$	(122.9	)	$	(9.1	)	$	0.1		$	(141.0	)
	Reclassification adjustments from OCI are included in the table below:
	(in millions)	Three Months Ended November 30, 2014			Three Months Ended November 30, 2013			Six Months Ended November 30, 2014			Six Months Ended November 30, 2013			Location on Statement of Operations
	Interest rate swaps	$	2.5		$	28.6		$	7.3		$	36.1		Interest expense
	The tax effects in other comprehensive income (loss) are included in the tables below:
		Three Months Ended November 30, 2014									Three Months Ended November 30, 2013
	(in millions)	Before Tax			Tax			Net of Tax			Before Tax			Tax			Net of Tax
	Unrecognized actuarial gains (losses)	$	2.3		$	(0.7	)	$	1.6		$	(0.2	)	$	—		$	(0.2	)
	Foreign currency translation adjustments	(152.0		)	14.7			(137.3		)	26			1.2			27.2
	Unrealized gain (loss) on interest rate swaps	(2.7		)	0.7			(2.0		)	(18.1		)	9.1			(9.0		)
	Reclassifications on interest rate swaps	2.5			(0.9		)	1.6			28.6			(10.8		)	17.8
	Unrealized gain (loss) on available-for-sale securities	—			—			—			2.7			(1.4		)	1.3
	Other comprehensive income (loss)	$	(149.9	)	$	13.8		$	(136.1	)	$	39		$	(1.9	)	$	37.1
		Six Months Ended November 30, 2014									Six Months Ended November 30, 2013
	(in millions)	Before Tax			Tax			Net of Tax			Before Tax			Tax			Net of Tax
	Unrecognized actuarial gains (losses)	$	2.7		$	(0.8	)	$	1.9		$	—		$	—		$	—
	Foreign currency translation adjustments	(203.8		)	18.3			(185.5		)	18.2			13.5			31.7
	Unrealized gain (loss) on interest rate swaps	(5.7		)	4.3			(1.4		)	(9.4		)	9.3			(0.1		)
	Reclassifications on interest rate swaps	7.3			(2.7		)	4.6			36.1			(13.7		)	22.4
	Unrealized gain (loss) on available-for-sale securities	0.1			—			0.1			2.7			(1.4		)	1.3
	Other comprehensive income (loss)	$	(199.4	)	$	19.1		$	(180.3	)	$	47.6		$	7.7		$	55.3

Segment_Reporting_Tables

Segment Reporting (Tables)	6 Months Ended
	Nov. 30, 2014
Segment Reporting [Abstract]
Net Sales by Product Category	Net sales by product category for the three and six months ended November 30, 2014 and 2013 were as follows:
		Three Months Ended				Six Months Ended
	(in millions)	November 30, 2014		30-Nov-13		30-Nov-14		30-Nov-13
	Net sales by product:
	Knees	$	264.3	$	264	$	499	$	489.1
	Hips	168		167.7		323.3		317.4
	S.E.T.	160.6		160.3		315.1		309.8
	Spine, Bone Healing and Microfixation	124.5		104.9		247.3		206.5
	Dental	67.6		70.5		121.3		124.4
	Cement, Biologics and Other	58.6		58.3		112.4		109.2
	Total	$	843.6	$	825.7	$	1,618.40	$	1,556.40
Net Sales by Geography	Net sales by geography for the three and six months ended November 30, 2014 and 2013 were as follows:
		Three Months Ended				Six Months Ended
	(in millions)	November 30, 2014		30-Nov-13		30-Nov-14		30-Nov-13
	Net sales by geography:
	United States	$	512.4	$	493.1	$	1,007.50	$	963
	Europe	206.1		211.8		367.4		363.3
	International(1)	125.1		120.8		243.5		230.1
	Total	$	843.6	$	825.7	$	1,618.40	$	1,556.40
	-1	International primarily includes Canada, Latin America and the Asia Pacific region.
Long-Term Assets by Geography	Long-term assets by geography as of November 30, 2014, May 31, 2014 and 2013 were as follows:
	(in millions)	30-Nov-14		May 31, 2014		May 31, 2013
	Long-term assets(1) by geography:
	United States	$	419.3	$	396.9	$	336.8
	Europe	173.4		241.4		255.7
	International	127.3		77.7		72.7
	Total	$	720	$	716	$	665.2
	-1	Defined as property, plant and equipment

Guarantor_and_NonGuarantor_Fin1

Guarantor and Non-Guarantor Financial Statements (Tables)	6 Months Ended
	Nov. 30, 2014
Text Block [Abstract]
Condensed Consolidating Balance Sheets	CONDENSED CONSOLIDATING BALANCE SHEETS
		30-Nov-14
	(in millions)	Biomet, Inc.			Guarantors			Non-Guarantors			Eliminations			Total
	Assets
	Current assets:
	Cash and cash equivalents	$	—		$	88.1		$	188.4		$	—		$	276.5
	Accounts receivable, net	—			290.3			275			—			565.3
	Inventories, net	—			404.9			316.8			—			721.7
	Deferred income taxes	—			118.2			28.8			—			147
	Prepaid expenses and other	—			135.9			51.8			—			187.7
	Total current assets	—			1,037.40			860.8			—			1,898.20
	Property, plant and equipment, net	—			430.8			289.2			—			720
	Investments	—			12.9			0.6			—			13.5
	Investment in subsidiaries	7,799.20			—			—			(7,799.2		)	—
	Intangible assets, net	—			2,610.80			607.8			—			3,218.60
	Goodwill	—			3,143.50			433.6			—			3,577.10
	Other assets	—			119.9			10.8			—			130.7
	Total assets	$	7,799.20		$	7,355.30		$	2,202.80		$	(7,799.2	)	$	9,558.10
	Liabilities & Shareholder’s Equity
	Current liabilities:
	Current portion of long-term debt	$	132.8		$	—		$	—		$	—		$	132.8
	Accounts payable	—			60.5			41.6			—			102.1
	Accrued interest	50.6			—			0.1			—			50.7
	Accrued wages and commissions	—			67.3			56.1			—			123.4
	Other accrued expenses	—			282.7			70.9			—			353.6
	Total current liabilities	183.4			410.5			168.7			—			762.6
	Long-term debt	5,581.90			—			—			—			5,581.90
	Deferred income taxes	—			765.9			154.4			—			920.3
	Other long-term liabilities	—			172.8			86.6			—			259.4
	Total liabilities	5,765.30			1,349.20			409.7			—			7,524.20
	Shareholder’s equity	2,033.90			6,006.10			1,793.10			(7,799.2		)	2,033.90
	Total liabilities and shareholder’s equity	$	7,799.20		$	7,355.30		$	2,202.80		$	(7,799.2	)	$	9,558.10
		May 31, 2014
	(in millions)	Biomet, Inc.			Guarantors			Non-Guarantors			Eliminations			Total
	Assets
	Current assets:
	Cash and cash equivalents	$	—		$	101.8		$	145.8		$	—		$	247.6
	Accounts receivable, net	—			284.6			292.7			—			577.3
	Inventories	—			374.3			319.1			—			693.4
	Deferred income taxes	—			117.9			32			—			149.9
	Prepaid expenses and other	—			128			74.9			—			202.9
	Total current assets	—			1,006.60			864.5			—			1,871.10
	Property, plant and equipment, net	—			412.4			303.6			—			716
	Investments	—			11.9			0.6			—			12.5
	Investment in subsidiaries	7,882.90			—			—			(7,882.9		)	—
	Intangible assets, net	—			2,740.10			699.5			—			3,439.60
	Goodwill	—			3,146.70			487.7			—			3,634.40
	Other assets	—			81.5			11.5			—			93
	Total assets	$	7,882.90		$	7,399.20		$	2,367.40		$	(7,882.9	)	$	9,766.60
	Liabilities & Shareholder’s Equity
	Current liabilities:
	Current portion of long-term debt	$	133.1		$	—		$	—		$	—		$	133.1
	Accounts payable	—			86.9			48.4			—			135.3
	Accrued interest	53.3			—			0.1			—			53.4
	Accrued wages and commissions	—			90			78.7			—			168.7
	Other accrued expenses	—			259.4			95.3			—			354.7
	Total current liabilities	186.4			436.3			222.5			—			845.2
	Long-term debt	5,587.30			—			—			—			5,587.30
	Deferred income taxes	—			811.3			157.3			—			968.6
	Other long-term liabilities	—			170.8			85.5			—			256.3
	Total liabilities	5,773.70			1,418.40			465.3			—			7,657.40
	Shareholder’s equity	2,109.20			5,980.80			1,902.10			(7,882.9		)	2,109.20
	Total liabilities and shareholder’s equity	$	7,882.90		$	7,399.20		$	2,367.40		$	(7,882.9	)	$	9,766.60
Condensed Consolidating Statements of Operations and Comprehensive Income (Loss)	CONDENSED CONSOLIDATING STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS)
		Three Months Ended November 30, 2014
	(in millions)	Biomet, Inc.			Guarantors			Non-Guarantors			Eliminations			Total
	Net sales	$	—		$	532.5		$	311.1		$	—		$	843.6
	Cost of sales	—			158.5			25.3			—			183.8
	Gross profit	—			374			285.8			—			659.8
	Selling, general and administrative expense	—			238.5			129.2			—			367.7
	Research and development expense	—			32			10.9			—			42.9
	Amortization	—			60.6			19			—			79.6
	Operating income	—			42.9			126.7			—			169.6
	Interest expense	78.5			—			—			—			78.5
	Other (income) expense	—			5.9			(8.0		)	—			(2.1		)
	Income (loss) before income taxes	(78.5		)	37			134.7			—			93.2
	Tax expense (benefit)	(29.8		)	14			19.2			—			3.4
	Equity in earnings of subsidiaries	138.5			—			—			(138.5		)	—
	Net income (loss)	$	89.8		$	23		$	115.5		$	(138.5	)	$	89.8
	Other comprehensive income (loss)	$	(136.1	)	$	—		$	(135.7	)	$	135.7		$	(136.1	)
	Total comprehensive income (loss)	$	(46.3	)	$	23		$	(20.2	)	$	(2.8	)	$	(46.3	)
		Three Months Ended November 30, 2013
	(in millions)	Biomet, Inc.			Guarantors			Non-Guarantors			Eliminations			Total
	Net sales	$	—		$	510.6		$	315.1		$	—		$	825.7
	Cost of sales	—			221.5			33.6			—			255.1
	Gross profit	—			289.1			281.5			—			570.6
	Selling, general and administrative expense	—			209.6			130.8			—			340.4
	Research and development expense	—			30.3			11.1			—			41.4
	Amortization	—			61.8			13.4			—			75.2
	Operating income (loss)	—			(12.6		)	126.2			—			113.6
	Interest expense	106.1			—			(0.4		)	—			105.7
	Other (income) expense	4.8			(1.2		)	0.1			—			3.7
	Income (loss) before income taxes	(110.9		)	(11.4		)	126.5			—			4.2
	Tax expense (benefit)	(42.1		)	(4.3		)	45.7			—			(0.7		)
	Equity in earnings of subsidiaries	73.7			—			—			(73.7		)	—
	Net income (loss)	$	4.9		$	(7.1	)	$	80.8		$	(73.7	)	$	4.9
	Other comprehensive income (loss)	$	8.8		$	—		$	28.3		$	—		$	37.1
	Total comprehensive income (loss)	$	13.7		$	(7.1	)	$	109.1		$	(73.7	)	$	42
Condensed Consolidating Statements of Cash Flows	CONDENSED CONSOLIDATING STATEMENTS OF CASH FLOW
		Six Months Ended November 30, 2014
	(in millions)	Biomet, Inc.			Guarantor			Non-Guarantors			Eliminations			Total
	Cash flows provided by (used in) operating activities	$	3		$	60.9		$	98.8		$	—		$	162.7
	Proceeds from sales/maturities of investments	—			—			15.2			—			15.2
	Purchases of investments	—			—			(16.3		)	—			(16.3		)
	Capital expenditures	—			(74.3		)	(57.8		)	—			(132.1		)
	Other	—			(0.6		)	—			—			(0.6		)
	Cash flows provided by (used in) investing activities	—			(74.9		)	(58.9		)	—			(133.8		)
	Proceeds under revolvers	205			—			—			—			205
	Payments under revolver	(20.0		)	—			—			—			(20.0		)
	Retirement of term loans	(180.0		)	—			—			—			(180.0		)
	Other	(8.0		)	0.3			—			—			(7.7		)
	Cash flows provided by (used in) financing activities	(3.0		)	0.3			—			—			(2.7		)
	Effect of exchange rate changes on cash	—			—			2.7			—			2.7
	Increase (decrease) in cash and cash equivalents	—			(13.7		)	42.6			—			28.9
	Cash and cash equivalents, beginning of period	—			101.8			145.8			—			247.6
	Cash and cash equivalents, end of period	$	—		$	88.1		$	188.4		$	—		$	276.5
		Six Months Ended November 30, 2013
	(in millions)	Biomet, Inc.			Guarantor			Non-Guarantors			Eliminations			Total
	Cash flows provided by (used in) operating activities	$	96.5		$	278.5		$	(204.1	)	$	—		$	170.9
	Proceeds from sales/maturities of investments	—			19			—						19
	Purchases of investments	—			(19.6		)	—						(19.6		)
	Capital expenditures	—			(53.9		)	(44.6		)	—			(98.5		)
	Acquisitions, net of cash acquired - 2013 Spine Acquisition	—			(148.8		)	—			—			(148.8		)
	Other	—			(0.8		)	0.1			—			(0.7		)
	Cash flows provided by (used in) investing activities	—			(204.1		)	(44.5		)	—			(248.6		)
	Payments under senior secured credit facilities	(14.9		)	—			—			—			(14.9		)
	Proceeds under revolvers	155			—			4.3			—			159.3
	Proceeds from senior notes due 2020 and term loans	870.5			—			—			—			870.5
	Retirement of term loans	(1,091.6		)	—			—			—			(1,091.6		)
	Payment of fees related to refinancing activities	(15.5		)	—			—			—			(15.5		)
	Other	—			0.3			(9.3		)	—			(9.0		)
	Cash flows provided by (used in) financing activities	(96.5		)	0.3			(5.0		)	—			(101.2		)
	Effect of exchange rate changes on cash	—			—			(0.5		)	—			(0.5		)
	Decrease in cash and cash equivalents	—			74.7			(254.1		)	—			(179.4		)
	Cash and cash equivalents, beginning of period	—			35.3			320.3			—			355.6
	Cash and cash equivalents, end of period	$	—		$	110		$	66.2		$	—		$	176.2

Restructuring_Tables

Restructuring (Tables)	6 Months Ended
	Nov. 30, 2014
Restructuring and Related Activities [Abstract]
Summary of severance and benefit costs
	(in millions)	Restructuring Costs
	Restructuring Accrual:
	Balance at May 31, 2014	$	42.5
	Costs incurred and charged to expense	1.8
	Costs paid or otherwise settled	(21.0		)
	Non-cash adjustments(1)	(0.2		)
	Balance at August 31, 2014	23.1
	Costs incurred and charged to expense	3.2
	Costs paid or otherwise settled	(2.5		)
	Non-cash adjustments(1)	—
	Balance at November 30, 2014	$	23.8
	-1	Primarily related to foreign currency fluctuations.
	(in millions)	Restructuring Costs
	Restructuring Accrual:
	Balance at May 31, 2013	$	8.9
	Costs incurred and charged to expense	6.3
	Costs paid or otherwise settled	(5.3		)
	Non-cash adjustments(1)	0.7
	Balance at August 31, 2013	10.6
	Costs incurred and charged to expense	5.9
	Costs paid or otherwise settled	(3.9		)
	Non-cash adjustments(1)	0.8
	Balance at November 30, 2013	$	13.4
	-1	Primarily related to foreign currency fluctuations.

Basis_of_Presentation_Details

Basis of Presentation (Details) (LVB Acquisition, Inc. [Member], USD $)	0 Months Ended	7 Months Ended
	Apr. 24, 2014	Nov. 30, 2014	Oct. 03, 2014
Business Acquisition [Line Items]
Shares eligible to vote on Merger Approval			536,034,330
Shares eligible to vote on Merger Approval as a percentage of outstanding stock			97.00%
Zimmer [Member]
Business Acquisition [Line Items]
Aggregate purchase price	$13,350,000,000
Cash paid to acquire business	10,350,000,000
Number of shares issued in acquisition	32,704,677
Equity interest issued as consideration	3,000,000,000
Share price	$91.73
Number of consecutive trading days used to determine the basis of share price	5 days
Repayments of outstanding debt		$5,714,700,000
Days to consummate merger	15 days

Recent_Acquisitions_by_Biomet_1

Recent Acquisitions by Biomet - Additional Information (Detail) (Lanx, Inc. [Member], USD $)	0 Months Ended
In Millions, unless otherwise specified	Oct. 05, 2013
Lanx, Inc. [Member]
Business Acquisition [Line Items]
Aggregate purchase price	$150.80

Recent_Acquisitions_by_Biomet_2

Recent Acquisitions by Biomet - Purchase Price Allocation (Detail) (USD $)	Nov. 30, 2014	31-May-14	Oct. 05, 2013
In Millions, unless otherwise specified
Business Acquisition [Line Items]
Goodwill	$3,577.10	$3,634.40
Lanx, Inc. [Member]
Business Acquisition [Line Items]
Cash			2
Accounts receivable			16.5
Inventory			24.8
Prepaid expenses and other			11
Instruments			9.9
Other property, plant and equipment			2.1
Deferred tax liability			-36.8
Other liabilities assumed			-20.7
Intangible assets			102.3
Goodwill			39.7
Preliminary purchase price			$150.80

Recent_Acquisitions_by_Biomet_3

Recent Acquisitions by Biomet - Pro Forma Information (Details) (USD $)	6 Months Ended		3 Months Ended
In Millions, unless otherwise specified	Nov. 30, 2014	Nov. 30, 2013	Nov. 30, 2013
Business Acquisition [Line Items]
Amortization and depreciation of assets	$249.10	$242.50
Transaction costs		4.1	4.1
Lanx, Inc. [Member]
Business Acquisition [Line Items]
Pro forma net sales		1,595.30	841.5
Pro forma net income (loss)		35.2	7.6
Amortization and depreciation of assets		$1.90	$0.80

Inventories_Components_of_Inve

Inventories - Components of Inventories (Detail) (USD $)	Nov. 30, 2014	31-May-14
In Millions, unless otherwise specified
Inventory Disclosure [Abstract]
Raw materials	$91.30	$83.10
Work-in-process	48.2	54.4
Finished goods	582.2	555.9
Inventories	$721.70	$693.40

Property_Plant_and_Equipment_U

Property, Plant and Equipment - Useful Lives of Property, Plant and Equipment (Detail)	6 Months Ended
	Nov. 30, 2014
Land improvements [Member]
Property, Plant and Equipment [Line Items]
Useful life of property, plant and equipment	20 years
Buildings and leasehold improvements [Member]
Property, Plant and Equipment [Line Items]
Useful life of property, plant and equipment	30 years
Machinery and equipment [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Useful life of property, plant and equipment	5 years
Machinery and equipment [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Useful life of property, plant and equipment	10 years
Instruments [Member]
Property, Plant and Equipment [Line Items]
Useful life of property, plant and equipment	4 years

Property_Plant_and_Equipment_C

Property, Plant and Equipment - Components of Property, Plant and Equipment (Detail) (USD $)	3 Months Ended		6 Months Ended
In Millions, unless otherwise specified	Nov. 30, 2014	Nov. 30, 2013	Nov. 30, 2014	Nov. 30, 2013	31-May-14
Property, Plant and Equipment [Line Items]
Total property, plant and equipment	$1,446.40		$1,446.40		$1,421.90
Accumulated depreciation	-726.4		-726.4		-705.9
Total property, plant and equipment, net	720		720		716
Depreciation expense	47.9	97.6	46.9	91.8
Land and land improvements [Member}
Property, Plant and Equipment [Line Items]
Total property, plant and equipment	40.4		40.4		40.8
Buildings and leasehold improvements [Member]
Property, Plant and Equipment [Line Items]
Total property, plant and equipment	124.5		124.5		126.8
Machinery and equipment [Member]
Property, Plant and Equipment [Line Items]
Total property, plant and equipment	431.2		431.2		414.5
Instruments [Member]
Property, Plant and Equipment [Line Items]
Total property, plant and equipment	814.2		814.2		791.9
Construction in progress [Member]
Property, Plant and Equipment [Line Items]
Total property, plant and equipment	$36.10		$36.10		$47.90

Investments_Summary_of_Company

Investments - Summary of Company's Investment Securities (Detail) (USD $)	6 Months Ended	12 Months Ended
In Millions, unless otherwise specified	Nov. 30, 2014	31-May-14
Summary of Investment Holdings [Line Items]
Available-for-sale, Amortized Cost	$10.70	$10.40
Available-for-sale, Unrealized Gains	0.1	0.6
Available-for-sale, Unrealized Losses	-0.1	-0.3
Available-for-sale, Fair Value	10.7	10.7
Trading, Amortized Cost	2.7	1.6
Trading, Realized Gains	0.1	0.3
Trading, Realized Losses	0	-0.1
Trading, Fair Value	2.8	1.8
Equity securities [Member]
Summary of Investment Holdings [Line Items]
Available-for-sale, Amortized Cost	0.5	0.2
Available-for-sale, Unrealized Gains	0.1	0.6
Available-for-sale, Unrealized Losses	0	-0.3
Available-for-sale, Fair Value	0.6	0.5
Trading, Amortized Cost	2.7	1.6
Trading, Realized Gains	0.1	0.3
Trading, Realized Losses	0	-0.1
Trading, Fair Value	2.8	1.8
Time deposit [Member]
Summary of Investment Holdings [Line Items]
Available-for-sale, Amortized Cost	10.2	10.2
Available-for-sale, Unrealized Gains	0	0
Available-for-sale, Unrealized Losses	-0.1	0
Available-for-sale, Fair Value	$10.10	$10.20

Investments_Additional_Informa

Investments - Additional Information (Detail) (USD $)	3 Months Ended		6 Months Ended
	Nov. 30, 2014	Nov. 30, 2013	Nov. 30, 2014	Nov. 30, 2013
Investments, Debt and Equity Securities [Abstract]
Proceeds on sales/maturities of investments	$15,200,000	$9,500,000	$15,200,000	$19,000,000
Investment purchases	$0	$10,100,000	$16,300,000	$19,600,000

Goodwill_and_Other_Intangible_2

Goodwill and Other Intangible Assets - Additional Information (Detail) (USD $)	Nov. 30, 2014	31-May-14
In Millions, unless otherwise specified
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill	$3,577.10	$3,634.40
Intangible assets, expected amortization expense for the remainder of 2015	278.2
Intangible assets, expected amortization expense for the year 2016	273.3
Intangible assets, expected amortization expense for the year 2017	269.6
Intangible assets, expected amortization expense for the year 2018	252.3
Intangible assets, expected amortization expense for the year 2019	$246.30

Goodwill_and_Other_Intangible_3

Goodwill and Other Intangible Assets - Schedule of Intangible Assets (Detail) (USD $)	Nov. 30, 2014	31-May-14
In Millions, unless otherwise specified
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	$5,211.40	$5,309.60
Accumulated Amortization	-1,992.80	-1,870
Net Carrying Amount	3,218.60	3,439.60
Core technology [Member]
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	1,748.90	1,743.30
Accumulated Amortization	-605.4	-569.8
Net Carrying Amount	1,143.50	1,173.50
Completed technology [Member]
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	662.7	672
Accumulated Amortization	-281.3	-262.1
Net Carrying Amount	381.4	409.9
Product trade names [Member]
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	188.8	208.1
Accumulated Amortization	-80.4	-77.6
Net Carrying Amount	108.4	130.5
Customer relationships [Member]
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	2,304.70	2,371.60
Accumulated Amortization	-1,021.10	-955.9
Net Carrying Amount	1,283.60	1,415.70
Non-compete contracts [Member]
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	4.9	4.9
Accumulated Amortization	-4.6	-4.6
Net Carrying Amount	0.3	0.3
Sub-total [Member]
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	4,910	4,999.90
Accumulated Amortization	-1,992.80	-1,870
Net Carrying Amount	2,917.20	3,129.90
Corporate trade names [Member]
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	301.4	309.7
Accumulated Amortization	0	0
Net Carrying Amount	$301.40	$309.70

Goodwill_and_Other_Intangible_4

Goodwill and Other Intangible Assets - Weighted Average Useful Life of Intangible Assets (Detail)	6 Months Ended
	Nov. 30, 2014
Core technology [Member]
Goodwill And Other Intangible Assets [Line Items]
Weighted Average Useful Life	14 years
Completed technology [Member]
Goodwill And Other Intangible Assets [Line Items]
Weighted Average Useful Life	8 years
Product trade names [Member]
Goodwill And Other Intangible Assets [Line Items]
Weighted Average Useful Life	12 years
Customer relationships [Member]
Goodwill And Other Intangible Assets [Line Items]
Weighted Average Useful Life	13 years
Non-compete contracts [Member]
Goodwill And Other Intangible Assets [Line Items]
Weighted Average Useful Life	1 year
Corporate trade names [Member]
Goodwill And Other Intangible Assets [Line Items]
Weighted Average Useful Life	Indefinite life

Debt_Schedule_of_Terms_and_Car

Debt - Schedule of Terms and Carrying Value of Debt Instrument (Detail) (USD $)	6 Months Ended	0 Months Ended
In Millions, unless otherwise specified	Nov. 30, 2014	Sep. 25, 2013	31-May-14
Debt Instrument [Line Items]
Premium on notes	$29.80		$32.50
Total debt	5,714.70		5,720.40
Asset-based revolving credit facility, 25-Jul-17 [Member] | Revolving Credit Facility [Member]
Debt Instrument [Line Items]
Total debt	185
Line of Credit [Member] | Cash flow revolving credit facility, 25-Apr-17 [Member] | Revolving Credit Facility [Member]
Debt Instrument [Line Items]
Maturity period of term loan under the credit facility	25-Apr-17
Total debt	0		0
Line of Credit [Member] | Cash flow revolving credit facility, 25-Apr-17 [Member] | Revolving Credit Facility [Member] | LIBOR [Member]
Debt Instrument [Line Items]
Debt instruments basis spread on variable rate	3.50%
Line of Credit [Member] | Asset-based revolving credit facility, 25-Jul-17 [Member] | Revolving Credit Facility [Member]
Debt Instrument [Line Items]
Maturity period of term loan under the credit facility	25-Jul-17
Total debt	185		0
Line of Credit [Member] | Asset-based revolving credit facility, 25-Jul-17 [Member] | Revolving Credit Facility [Member] | LIBOR [Member]
Debt Instrument [Line Items]
Debt instruments basis spread on variable rate	2.00%
Senior notes [Member] | 6.500% senior notes due 2020 [Member]
Debt Instrument [Line Items]
Maturity period of term loan under the credit facility	1-Aug-20
Interest rate	6.50%
Total debt	1,825		1,825
Senior Subordinated Notes [Member] | 6.500% senior notes due 2020 [Member]
Debt Instrument [Line Items]
Interest rate	6.50%
Senior Subordinated Notes [Member] | 6.500% senior subordinated notes due 2020 [Member]
Debt Instrument [Line Items]
Maturity period of term loan under the credit facility	1-Oct-20
Interest rate	6.50%
Total debt	800		800
USD [Member] | Term Loan [Member] | LIBOR [Member]
Debt Instrument [Line Items]
Debt instruments basis spread on variable rate		3.50%
USD [Member] | Term Loan [Member] | Term loan facility, 25-Mar-15 [Member]
Debt Instrument [Line Items]
Maturity period of term loan under the credit facility	25-Mar-15
Total debt	102.7		103.3
USD [Member] | Term Loan [Member] | Term loan facility, 25-Mar-15 [Member] | LIBOR [Member]
Debt Instrument [Line Items]
Debt instruments basis spread on variable rate	3.00%
USD [Member] | Term Loan [Member] | Term loan facility, 25-Jul-17 [Member]
Debt Instrument [Line Items]
Maturity period of term loan under the credit facility	25-Jul-17
Total debt	$2,772.20		$2,959.60
USD [Member] | Term Loan [Member] | Term loan facility, 25-Jul-17 [Member] | LIBOR [Member]
Debt Instrument [Line Items]
Debt instruments basis spread on variable rate	3.50%

Debt_Additional_Information_De

Debt - Additional Information (Detail)

Nov. 30, 2014

31-May-14

Nov. 30, 2014

Nov. 30, 2014

31-May-14

Nov. 30, 2014

Nov. 30, 2014

31-May-14

Nov. 30, 2014

Nov. 30, 2014

Sep. 25, 2013

Nov. 30, 2014

Sep. 25, 2013

Nov. 30, 2014

31-May-14

Nov. 30, 2014

Sep. 25, 2013

Sep. 25, 2013

Sep. 10, 2013

Sep. 10, 2013

Sep. 25, 2013

In Millions, unless otherwise specified

USD ($)

USD ($)

Asset-based revolving credit facility [Member]

Senior notes [Member]

Senior notes [Member]

Senior Subordinated Notes [Member]

Senior Subordinated Notes [Member]

Senior Subordinated Notes [Member]

Term Loan [Member]

Term Loan [Member]

USD [Member]

USD [Member]

USD [Member]

USD [Member]

USD [Member]

USD [Member]

EUR [Member]

EUR [Member]

EUR [Member]

EUR [Member]

EUR [Member]

Revolving Credit Facility [Member]

6.500% senior notes due 2020 [Member]

6.500% senior notes due 2020 [Member]

6.500% senior notes due 2020 [Member]

6.500% senior subordinated notes due 2020 [Member]

6.500% senior subordinated notes due 2020 [Member]

USD ($)

Term B-1 Loans [Member]

Term Loan [Member]

Term Loan [Member]

Term Loan [Member]

Term Loan [Member]

Term Loan [Member]

Term Loan [Member]

Term Loan [Member]

Term Loan [Member]

Term Loan [Member]

Term Loan [Member]

Term Loan [Member]

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

One-month LIBOR [Member]

LIBOR [Member]

Term B-1 Loans [Member]

Term B-1 Loans [Member]

Term B-1 Loans [Member]

USD ($)

EUR (€)

USD ($)

EUR (€)

USD ($)

USD ($)

USD ($)

LIBOR [Member]

Debt Disclosure [Line Items]

Interest rate

6.50%

6.50%

6.50%

Maturity year

2020

2020

2020

Percent of term loans subject to variable rate

100.00%

Variable rate basis

0.16%

Term loan payment in each year, Percentage

0.25%

0.25%

Total amount of required payments under the term loan facilities

$8

Revolving borrowing base

494.8

Financing fees related to credit agreement

62.7

Face value of bonds

870.5

870.5

Term loan

2,111.40

Outstanding balance

5,714.70

5,720.40

185

1,825

1,825

800

800

102.7

103.3

Debt retired

$870.20

€ 657.70

$221.40

€ 167.30

Debt instruments basis spread on variable rate

3.50%

3.00%

Fair_Value_Measurements_Fair_V

Fair Value Measurements - Fair Value of Assets and Liabilities Measured on Recurring Basis (Detail) (USD $)	Nov. 30, 2014	31-May-14	Nov. 30, 2013
Liabilities:
Fair value of long-term debt	$5,846,900,000	$5,912,900,000
Carrying value of long-term debt	5,714,700,000	5,720,400,000
Fair value of assets measured on a nonrecurring basis	0		0
Fair value of liabilities measured on a nonrecurring basis	0		0
Recurring [Member]
Assets:
Total assets, Fair Value	289,100,000	319,900,000
Liabilities:
Total liabilities, Fair Value	15,900,000	21,500,000
Recurring [Member] | Money market funds [Member]
Assets:
Total assets, Fair Value	124,600,000	145,000,000
Recurring [Member] | Time deposit [Member]
Assets:
Total assets, Fair Value	10,200,000	25,800,000
Recurring [Member] | Pension plan assets [Member]
Assets:
Total assets, Fair Value	144,900,000	147,500,000
Recurring [Member] | Foreign currency exchange contracts [Member]
Assets:
Total assets, Fair Value	6,000,000	1,100,000
Liabilities:
Total liabilities, Fair Value	400,000	1,300,000
Recurring [Member] | Equity securities [Member]
Assets:
Total assets, Fair Value	3,400,000	500,000
Recurring [Member] | Interest rate swaps [Member]
Liabilities:
Total liabilities, Fair Value	15,500,000	20,200,000
Recurring [Member] | Level 1 [Member]
Assets:
Total assets, Fair Value	127,800,000	145,300,000
Liabilities:
Total liabilities, Fair Value	0	0
Recurring [Member] | Level 1 [Member] | Money market funds [Member]
Assets:
Total assets, Fair Value	124,600,000	145,000,000
Recurring [Member] | Level 1 [Member] | Time deposit [Member]
Assets:
Total assets, Fair Value	0	0
Recurring [Member] | Level 1 [Member] | Pension plan assets [Member]
Assets:
Total assets, Fair Value	0	0
Recurring [Member] | Level 1 [Member] | Foreign currency exchange contracts [Member]
Assets:
Total assets, Fair Value	0	0
Liabilities:
Total liabilities, Fair Value	0	0
Recurring [Member] | Level 1 [Member] | Equity securities [Member]
Assets:
Total assets, Fair Value	3,200,000	300,000
Recurring [Member] | Level 1 [Member] | Interest rate swaps [Member]
Liabilities:
Total liabilities, Fair Value	0	0
Recurring [Member] | Level 2 [Member]
Assets:
Total assets, Fair Value	146,100,000	159,400,000
Liabilities:
Total liabilities, Fair Value	15,900,000	21,500,000
Recurring [Member] | Level 2 [Member] | Money market funds [Member]
Assets:
Total assets, Fair Value	0	0
Recurring [Member] | Level 2 [Member] | Time deposit [Member]
Assets:
Total assets, Fair Value	10,200,000	25,800,000
Recurring [Member] | Level 2 [Member] | Pension plan assets [Member]
Assets:
Total assets, Fair Value	129,900,000	132,500,000
Recurring [Member] | Level 2 [Member] | Foreign currency exchange contracts [Member]
Assets:
Total assets, Fair Value	6,000,000	1,100,000
Liabilities:
Total liabilities, Fair Value	400,000	1,300,000
Recurring [Member] | Level 2 [Member] | Equity securities [Member]
Assets:
Total assets, Fair Value	0	0
Recurring [Member] | Level 2 [Member] | Interest rate swaps [Member]
Liabilities:
Total liabilities, Fair Value	15,500,000	20,200,000
Recurring [Member] | Level 3 [Member]
Assets:
Total assets, Fair Value	15,200,000	15,200,000
Liabilities:
Total liabilities, Fair Value	0	0
Recurring [Member] | Level 3 [Member] | Money market funds [Member]
Assets:
Total assets, Fair Value	0	0
Recurring [Member] | Level 3 [Member] | Time deposit [Member]
Assets:
Total assets, Fair Value	0	0
Recurring [Member] | Level 3 [Member] | Pension plan assets [Member]
Assets:
Total assets, Fair Value	15,000,000	15,000,000
Recurring [Member] | Level 3 [Member] | Foreign currency exchange contracts [Member]
Assets:
Total assets, Fair Value	0	0
Liabilities:
Total liabilities, Fair Value	0	0
Recurring [Member] | Level 3 [Member] | Equity securities [Member]
Assets:
Total assets, Fair Value	200,000	200,000
Recurring [Member] | Level 3 [Member] | Interest rate swaps [Member]
Liabilities:
Total liabilities, Fair Value	$0	$0

Derivative_Instruments_and_Hed2

Derivative Instruments and Hedging Activities - Additional Information (Detail) (USD $)	Nov. 30, 2014	31-May-14
In Millions, unless otherwise specified
Derivative Instruments And Hedging Activities [Line Items]
Hedged portion of net investment	$1,160
Hedged portion of net investment, as a percentage	41.84%
Swap liability	15.5	20.2
Derivatives not designated as hedging instruments on a gross basis assets	6	1.1
Not Designated as Hedging Instrument [Member] | Other Accrued Expenses [Member]
Derivative Instruments And Hedging Activities [Line Items]
Derivatives not designated as hedging instruments on a gross basis liabilities	0.4	1.3
Swap agreements [Member]
Derivative Instruments And Hedging Activities [Line Items]
Effective weighted average interest rate on all outstanding debt, including the interest rate swaps	5.15%	5.37%
Short-term [Member]
Derivative Instruments And Hedging Activities [Line Items]
Swap liability	6.7	8.8
Long-term [Member]
Derivative Instruments And Hedging Activities [Line Items]
Swap liability	9	11.6
Credit valuation adjustment [Member]
Derivative Instruments And Hedging Activities [Line Items]
Swap liability	($0.20)	($0.20)
U.S. dollar term loan [Member]
Derivative Instruments And Hedging Activities [Line Items]
Effective interest rate	3.62%
Term loan fixed interest rate	4.84%

Derivative_Instruments_and_Hed3

Derivative Instruments and Hedging Activities - Schedule of Summary Existing Swap Agreements (Detail) (USD $)	6 Months Ended
In Millions, unless otherwise specified	Nov. 30, 2014	31-May-14
Outstanding Interest Rate Swap Agreements [Line Items]
Fair Value Asset (Liability)	($15.50)	($20.20)
September 25, 2014 [Member] | Swap agreements [Member]
Outstanding Interest Rate Swap Agreements [Line Items]
Structure	5 years
Notional Amount	195
Effective Date	25-Sep-09
Termination Date	25-Sep-14
Fair Value Asset (Liability)	0	-1.7
March 25, 2015 [Member] | Swap agreements [Member]
Outstanding Interest Rate Swap Agreements [Line Items]
Structure	2 years
Notional Amount	190
Effective Date	25-Mar-13
Termination Date	25-Mar-15
Fair Value Asset (Liability)	-0.4	-1
September 25, 2016 [Member] | Swap agreements [Member]
Outstanding Interest Rate Swap Agreements [Line Items]
Structure	3 years
Notional Amount	270
Effective Date	27-Dec-13
Termination Date	25-Sep-16
Fair Value Asset (Liability)	-4.7	-5.8
September 25, 2017 [Member] | Swap agreements [Member]
Outstanding Interest Rate Swap Agreements [Line Items]
Structure	5 years
Notional Amount	350
Effective Date	25-Sep-12
Termination Date	25-Sep-17
Fair Value Asset (Liability)	-5.3	-5.9
September 25, 2017 [Member] | September 25, 2012 [Member] | Swap agreements [Member]
Outstanding Interest Rate Swap Agreements [Line Items]
Structure	5 years
Notional Amount	350
Effective Date	25-Sep-12
Termination Date	25-Sep-17
Fair Value Asset (Liability)	-5.3	-6
Credit valuation adjustment [Member]
Outstanding Interest Rate Swap Agreements [Line Items]
Fair Value Asset (Liability)	$0.20	$0.20

Derivative_Instruments_and_Hed4

Derivative Instruments and Hedging Activities - Schedule of Interest Rate Swap (Detail) (USD $)	3 Months Ended		6 Months Ended
In Millions, unless otherwise specified	Nov. 30, 2014	Nov. 30, 2013	Nov. 30, 2014	Nov. 30, 2013
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Amount of gain (loss) recognized in OCI	($0.60)	$4.50	$4.70	$26.20
Amount of (gain) loss reclassified from accumulated OCI into interest expense (effective portion)	2.5	6.8	7.3	14.3
Amount (gain) loss recognized in other income (expense) (ineffective portion and amount excluded from effectiveness testing)	$0	$21.80		$21.80

Accumulated_Other_Comprehensiv2

Accumulated Other Comprehensive Income (Loss) - Accumulated other comprehensive income (loss) and related components (Detail) (USD $)	6 Months Ended
In Millions, unless otherwise specified	Nov. 30, 2014
Accumulated Other Comprehensive Income (Loss), Net Of Tax [Roll Forward]
Beginning of period	$39.30
OCI before reclassifications	-184.9
Reclassifications	4.6
End of period	-141
Unrecognized Actuarial Gains (Losses) [Member]
Accumulated Other Comprehensive Income (Loss), Net Of Tax [Roll Forward]
Beginning of period	-11
OCI before reclassifications	1.9
Reclassifications	0
End of period	-9.1
Foreign Currency Translation Adjustments [Member]
Accumulated Other Comprehensive Income (Loss), Net Of Tax [Roll Forward]
Beginning of period	62.6
OCI before reclassifications	-185.5
Reclassifications	0
End of period	-122.9
Unrealized Gain (Loss) on Interest Rate Swaps [Member]
Accumulated Other Comprehensive Income (Loss), Net Of Tax [Roll Forward]
Beginning of period	-12.3
OCI before reclassifications	-1.4
Reclassifications	4.6
End of period	-9.1
Unrealized Gain (Loss) on Available-For-Sale Securities [Member]
Accumulated Other Comprehensive Income (Loss), Net Of Tax [Roll Forward]
Beginning of period	0
OCI before reclassifications	0.1
Reclassifications	0
End of period	$0.10

Accumulated_Other_Comprehensiv3

Accumulated Other Comprehensive Income (Loss) - Reclassification adjustments (Detail) (USD $)	3 Months Ended		6 Months Ended
In Millions, unless otherwise specified	Nov. 30, 2014	Nov. 30, 2013	Nov. 30, 2014	Nov. 30, 2013
Accumulated Other Comprehensive Income Loss [Line Items]
Reclassification adjustment, interest rate swaps	($1.60)	($17.80)	($4.60)	($22.40)
Interest Expense [Member]
Accumulated Other Comprehensive Income Loss [Line Items]
Reclassification adjustment, interest rate swaps	$2.50	$28.60	$7.30	$36.10

Accumulated_Other_Comprehensiv4

Accumulated Other Comprehensive Income (Loss) - Tax effects in other comprehensive income (Detail) (USD $)	3 Months Ended		6 Months Ended
In Millions, unless otherwise specified	Nov. 30, 2014	Nov. 30, 2013	Nov. 30, 2014	Nov. 30, 2013
Equity [Abstract]
Unrecognized actuarial gains (losses), before tax	$2.30	($0.20)	$2.70	$0
Unrecognized actuarial gains (losses), tax	-0.7	0	-0.8	0
Unrecognized actuarial gains (losses), net of tax	1.6	-0.2	1.9	0
Foreign currency translation adjustments, before tax	-152	26	-203.8	18.2
Foreign currency translation adjustments, tax	14.7	1.2	18.3	13.5
Foreign currency translation adjustments, net tax	-137.3	27.2	-185.5	31.7
Unrealized gain (loss) on interest rate swaps, before tax	-2.7	-18.1	-5.7	-9.4
Unrealized gain (loss) on interest rate swaps, tax	0.7	9.1	4.3	9.3
Unrealized gain (loss) on interest rate swaps, net of tax	-2	-9	-1.4	-0.1
Reclassifications on interest rate swaps, before tax	2.5	28.6	7.3	36.1
Reclassifications on interest rate swaps, tax	-0.9	-10.8	-2.7	-13.7
Reclassifications on interest rate swaps, net of tax	1.6	17.8	4.6	22.4
Unrealized gain (loss) on available-for-sale securities, before tax	0	2.7	0.1	2.7
Unrealized gain (loss) on available-for-sale securities, tax	0	-1.4	0	-1.4
Unrealized gain (loss) on available-for-sale securities, net of tax	0	1.3	0.1	1.3
Accumulated other comprehensive income, before tax	-149.9	39	-199.4	47.6
Accumulated other comprehensive income, tax	13.8	-1.9	19.1	7.7
Other comprehensive income (loss)	($136.10)	$37.10	($180.30)	$55.30

Sharebased_Compensation_and_St1

Share-based Compensation and Stock Plans (Detail) (USD $)	3 Months Ended		6 Months Ended
In Millions, unless otherwise specified	Nov. 30, 2014	Nov. 30, 2013	Nov. 30, 2014	Nov. 30, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense recognized	$4.80	$4.50	$8.40	$9.20
2012 Restricted Stock Unit Plan [Member] | Restricted Stock Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of installments			3
Vesting period			2 years

Income_Taxes_Detail

Income Taxes (Detail) (USD $)	3 Months Ended		6 Months Ended
In Millions, unless otherwise specified	Nov. 30, 2014	Nov. 30, 2013	Nov. 30, 2014	Nov. 30, 2013
Income Tax Disclosure [Abstract]
Effective income tax rate	3.60%	-16.70%	2.70%	-233.30%
Increase in income tax benefit as a result of updated assertions regarding uncertain tax benefits	$3
Decrease in income tax provision due to release of valuation allowance		($26.10)
Increase in effective income tax rates	3.00%	-242.10%

Segment_Reporting_Net_Sales_by

Segment Reporting - Net Sales by Product Category (Detail) (USD $)	3 Months Ended		6 Months Ended
In Millions, unless otherwise specified	Nov. 30, 2014	Nov. 30, 2013	Nov. 30, 2014	Nov. 30, 2013
			reportable_segment
Revenues from External Customers and Long-Lived Assets [Line Items]
Number of reportable segments			1
Net sales by product:
Net sales	$843.60	$825.70	$1,618.40	$1,556.40
Knees [Member]
Net sales by product:
Net sales	264.3	264	499	489.1
Hips [Member]
Net sales by product:
Net sales	168	167.7	323.3	317.4
S.E.T. [Member]
Net sales by product:
Net sales	160.6	160.3	315.1	309.8
Spine & Bone Healing [Member]
Net sales by product:
Net sales	124.5	104.9	247.3	206.5
Dental [Member]
Net sales by product:
Net sales	67.6	70.5	121.3	124.4
Cement, Biologics & Other [Member]
Net sales by product:
Net sales	$58.60	$58.30	$112.40	$109.20

Segment_Reporting_Net_Sales_by1

Segment Reporting - Net Sales by Geography (Detail) (USD $)	3 Months Ended				6 Months Ended
In Millions, unless otherwise specified	Nov. 30, 2014		Nov. 30, 2013		Nov. 30, 2014		Nov. 30, 2013
Net sales by geography:
Net sales	$843.60		$825.70		$1,618.40		$1,556.40
United States
Net sales by geography:
Net sales	512.4		493.1		1,007.50		963
Europe
Net sales by geography:
Net sales	206.1		211.8		367.4		363.3
International
Net sales by geography:
Net sales	$125.10	[1]	$120.80	[1]	$243.50	[1]	$230.10	[1]
[1]	International primarily includes Canada, Latin America and the Asia Pacific region.

Segment_Reporting_LongTerm_Ass

Segment Reporting - Long-Term Assets by Geography (Detail) (USD $)	Nov. 30, 2014		31-May-14		31-May-13
In Millions, unless otherwise specified
Long-term assets by geography:
Long-term assets	$720	[1]	$716	[1]	$665.20	[1]
United States
Long-term assets by geography:
Long-term assets	419.3	[1]	396.9	[1]	336.8	[1]
Europe
Long-term assets by geography:
Long-term assets	173.4	[1]	241.4	[1]	255.7	[1]
International
Long-term assets by geography:
Long-term assets	$127.30	[1]	$77.70	[1]	$72.70	[1]
[1]	Defined as property, plant and equipment

Guarantor_and_NonGuarantor_Fin2

Guarantor and Non-Guarantor Financial Statements - Condensed Consolidating Balance Sheets (Detail) (USD $)	Nov. 30, 2014	31-May-14	Nov. 30, 2013	31-May-13
In Millions, unless otherwise specified
Current assets:
Cash and cash equivalents	$276.50	$247.60	$176.20	$355.60
Accounts receivable, net	565.3	577.3
Inventories, net	721.7	693.4
Deferred income taxes	147	149.9
Prepaid expenses and other	187.7	202.9
Total current assets	1,898.20	1,871.10
Property, plant and equipment, net	720	716
Investments	13.5	12.5
Intangible assets, net	3,218.60	3,439.60
Goodwill	3,577.10	3,634.40
Other assets	130.7	93
Total assets	9,558.10	9,766.60
Current liabilities:
Current portion of long-term debt	132.8	133.1
Accounts payable	102.1	135.3
Accrued interest	50.7	53.4
Accrued wages and commissions	123.4	168.7
Other accrued expenses	353.6	354.7
Total current liabilities	762.6	845.2
Long-term debt	5,581.90	5,587.30
Deferred income taxes	920.3	968.6
Other long-term liabilities	259.4	256.3
Total liabilities	7,524.20	7,657.40
Shareholder’s equity	2,033.90	2,109.20
Total liabilities and shareholders’ equity	9,558.10	9,766.60
Biomet, Inc [Member]
Current assets:
Cash and cash equivalents	0	0	0	0
Accounts receivable, net	0	0
Inventories, net	0	0
Deferred income taxes	0	0
Prepaid expenses and other	0	0
Total current assets	0	0
Property, plant and equipment, net	0	0
Investments	0	0
Investment in subsidiaries	7,799.20	7,882.90
Intangible assets, net	0	0
Goodwill	0	0
Other assets	0	0
Total assets	7,799.20	7,882.90
Current liabilities:
Current portion of long-term debt	132.8	133.1
Accounts payable	0	0
Accrued interest	50.6	53.3
Accrued wages and commissions	0	0
Other accrued expenses	0	0
Total current liabilities	183.4	186.4
Long-term debt	5,581.90	5,587.30
Deferred income taxes	0	0
Other long-term liabilities	0	0
Total liabilities	5,765.30	5,773.70
Shareholder’s equity	2,033.90	2,109.20
Total liabilities and shareholders’ equity	7,799.20	7,882.90
Guarantor [Member]
Current assets:
Cash and cash equivalents	88.1	101.8	110	35.3
Accounts receivable, net	290.3	284.6
Inventories, net	404.9	374.3
Deferred income taxes	118.2	117.9
Prepaid expenses and other	135.9	128
Total current assets	1,037.40	1,006.60
Property, plant and equipment, net	430.8	412.4
Investments	12.9	11.9
Investment in subsidiaries	0	0
Intangible assets, net	2,610.80	2,740.10
Goodwill	3,143.50	3,146.70
Other assets	119.9	81.5
Total assets	7,355.30	7,399.20
Current liabilities:
Current portion of long-term debt	0	0
Accounts payable	60.5	86.9
Accrued interest	0	0
Accrued wages and commissions	67.3	90
Other accrued expenses	282.7	259.4
Total current liabilities	410.5	436.3
Long-term debt	0	0
Deferred income taxes	765.9	811.3
Other long-term liabilities	172.8	170.8
Total liabilities	1,349.20	1,418.40
Shareholder’s equity	6,006.10	5,980.80
Total liabilities and shareholders’ equity	7,355.30	7,399.20
Non-Guarantors [Member]
Current assets:
Cash and cash equivalents	188.4	145.8	66.2	320.3
Accounts receivable, net	275	292.7
Inventories, net	316.8	319.1
Deferred income taxes	28.8	32
Prepaid expenses and other	51.8	74.9
Total current assets	860.8	864.5
Property, plant and equipment, net	289.2	303.6
Investments	0.6	0.6
Investment in subsidiaries	0	0
Intangible assets, net	607.8	699.5
Goodwill	433.6	487.7
Other assets	10.8	11.5
Total assets	2,202.80	2,367.40
Current liabilities:
Current portion of long-term debt	0	0
Accounts payable	41.6	48.4
Accrued interest	0.1	0.1
Accrued wages and commissions	56.1	78.7
Other accrued expenses	70.9	95.3
Total current liabilities	168.7	222.5
Long-term debt	0	0
Deferred income taxes	154.4	157.3
Other long-term liabilities	86.6	85.5
Total liabilities	409.7	465.3
Shareholder’s equity	1,793.10	1,902.10
Total liabilities and shareholders’ equity	2,202.80	2,367.40
Eliminations [Member]
Current assets:
Cash and cash equivalents	0	0	0	0
Accounts receivable, net	0	0
Inventories, net	0	0
Deferred income taxes	0	0
Prepaid expenses and other	0	0
Total current assets	0	0
Property, plant and equipment, net	0	0
Investments	0	0
Investment in subsidiaries	-7,799.20	-7,882.90
Intangible assets, net	0	0
Goodwill	0	0
Other assets	0	0
Total assets	-7,799.20	-7,882.90
Current liabilities:
Current portion of long-term debt	0	0
Accounts payable	0	0
Accrued interest	0	0
Accrued wages and commissions	0	0
Other accrued expenses	0	0
Total current liabilities	0	0
Long-term debt	0	0
Deferred income taxes	0	0
Other long-term liabilities	0	0
Total liabilities	0	0
Shareholder’s equity	-7,799.20	-7,882.90
Total liabilities and shareholders’ equity	-7,799.20	-7,882.90
Biomet, Inc. [Member]
Current assets:
Cash and cash equivalents	276.5	247.6	176.2	355.6
Accounts receivable, net	565.3	577.3
Inventories, net	721.7	693.4
Deferred income taxes	147	149.9
Prepaid expenses and other	187.7	202.9
Total current assets	1,898.20	1,871.10
Property, plant and equipment, net	720	716
Investments	13.5	12.5
Investment in subsidiaries	0	0
Intangible assets, net	3,218.60	3,439.60
Goodwill	3,577.10	3,634.40
Other assets	130.7	93
Total assets	9,558.10	9,766.60
Current liabilities:
Current portion of long-term debt	132.8	133.1
Accounts payable	102.1	135.3
Accrued interest	50.7	53.4
Accrued wages and commissions	123.4	168.7
Other accrued expenses	353.6	354.7
Total current liabilities	762.6	845.2
Long-term debt	5,581.90	5,587.30
Deferred income taxes	920.3	968.6
Other long-term liabilities	259.4	256.3
Total liabilities	7,524.20	7,657.40
Shareholder’s equity	2,033.90	2,109.20
Total liabilities and shareholders’ equity	$9,558.10	$9,766.60

Guarantor_and_NonGuarantor_Fin3

Guarantor and Non-Guarantor Financial Statements - Schedule of Condensed Statements of Operations and Comprehensive Income (Loss) (Detail) (USD $)	3 Months Ended		6 Months Ended
In Millions, unless otherwise specified	Nov. 30, 2014	Nov. 30, 2013	Nov. 30, 2014	Nov. 30, 2013
Schedule Of Condensed Statements Of Operations [Line Items]
Net sales	$843.60	$825.70	$1,618.40	$1,556.40
Cost of sales	183.8	255.1	399.7	463.1
Gross profit	659.8	570.6	1,218.70	1,093.30
Selling, general and administrative expense	367.7	340.4	729.4	653.7
Research and development expense	42.9	41.4	85.7	78.9
Amortization	79.6	75.2	151.5	150.7
Operating income	169.6	113.6	252.1	210
Interest expense	78.5	105.7	158.6	193.3
Other (income) expense	-2.1	3.7	-6.3	5.9
Income before income taxes	93.2	4.2	99.8	10.8
Net income	89.8	4.9	97.1	36
Other comprehensive income (loss)	-136.1	37.1	-180.3	55.3
Comprehensive income (loss)	-46.3	42	-83.2	91.3
Biomet, Inc [Member]
Schedule Of Condensed Statements Of Operations [Line Items]
Net sales	0	0	0	0
Cost of sales	0	0	0	0
Gross profit	0	0	0	0
Selling, general and administrative expense	0	0	0	0
Research and development expense	0	0	0	0
Amortization	0	0	0	0
Operating income	0	0	0	0
Interest expense	78.5	106.1	158.6	193.1
Other (income) expense	0	4.8	0	4.8
Income before income taxes	-78.5	-110.9	-158.6	-197.9
Tax expense (benefit)	-29.8	-42.1	-60.3	-75.2
Equity in earnings of subsidiaries	138.5	73.7	195.4	158.7
Net income	89.8	4.9	97.1	36
Other comprehensive income (loss)	-136.1	8.8	-180.3	22.3
Comprehensive income (loss)	-46.3	13.7	-83.2	58.3
Guarantor [Member]
Schedule Of Condensed Statements Of Operations [Line Items]
Net sales	532.5	510.6	1,041.30	992
Cost of sales	158.5	221.5	364.7	402.2
Gross profit	374	289.1	676.6	589.8
Selling, general and administrative expense	238.5	209.6	469.7	403.5
Research and development expense	32	30.3	63.4	58.2
Amortization	60.6	61.8	116.1	123.1
Operating income	42.9	-12.6	27.4	5
Interest expense	0	0	0	0
Other (income) expense	5.9	-1.2	11.1	-3.5
Income before income taxes	37	-11.4	16.3	8.5
Tax expense (benefit)	14	-4.3	6.1	3.3
Equity in earnings of subsidiaries	0	0	0	0
Net income	23	-7.1	10.2	5.2
Other comprehensive income (loss)	0	0	0.1	0
Comprehensive income (loss)	23	-7.1	10.3	5.2
Non-Guarantors [Member]
Schedule Of Condensed Statements Of Operations [Line Items]
Net sales	311.1	315.1	577.1	564.4
Cost of sales	25.3	33.6	35	60.9
Gross profit	285.8	281.5	542.1	503.5
Selling, general and administrative expense	129.2	130.8	259.7	250.2
Research and development expense	10.9	11.1	22.3	20.7
Amortization	19	13.4	35.4	27.6
Operating income	126.7	126.2	224.7	205
Interest expense	0	-0.4	0	0.2
Other (income) expense	-8	0.1	-17.4	4.6
Income before income taxes	134.7	126.5	242.1	200.2
Tax expense (benefit)	19.2	45.7	56.9	46.7
Equity in earnings of subsidiaries	0	0	0	0
Net income	115.5	80.8	185.2	153.5
Other comprehensive income (loss)	-135.7	28.3	-183.6	33
Comprehensive income (loss)	-20.2	109.1	1.6	186.5
Eliminations [Member]
Schedule Of Condensed Statements Of Operations [Line Items]
Net sales	0	0	0	0
Cost of sales	0	0	0	0
Gross profit	0	0	0	0
Selling, general and administrative expense	0	0	0	0
Research and development expense	0	0	0	0
Amortization	0	0	0	0
Operating income	0	0	0	0
Interest expense	0	0	0	0
Other (income) expense	0	0	0	0
Income before income taxes	0	0	0	0
Tax expense (benefit)	0	0	0	0
Equity in earnings of subsidiaries	-138.5	-73.7	-195.4	-158.7
Net income	-138.5	-73.7	-195.4	-158.7
Other comprehensive income (loss)	135.7	0	183.5	0
Comprehensive income (loss)	-2.8	-73.7	-11.9	-158.7
Biomet, Inc. [Member]
Schedule Of Condensed Statements Of Operations [Line Items]
Net sales	843.6	825.7	1,618.40	1,556.40
Cost of sales	183.8	255.1	399.7	463.1
Gross profit	659.8	570.6	1,218.70	1,093.30
Selling, general and administrative expense	367.7	340.4	729.4	653.7
Research and development expense	42.9	41.4	85.7	78.9
Amortization	79.6	75.2	151.5	150.7
Operating income	169.6	113.6	252.1	210
Interest expense	78.5	105.7	158.6	193.3
Other (income) expense	-2.1	3.7	-6.3	5.9
Income before income taxes	93.2	4.2	99.8	10.8
Tax expense (benefit)	3.4	-0.7	2.7	-25.2
Equity in earnings of subsidiaries	0	0	0	0
Net income	89.8	4.9	97.1	36
Other comprehensive income (loss)	-136.1	37.1	-180.3	55.3
Comprehensive income (loss)	($46.30)	$42	($83.20)	$91.30

Guarantor_and_NonGuarantor_Fin4

Guarantor and Non-Guarantor Financial Statements - Condensed Consolidating Statements of Cash Flow (Detail) (USD $)	3 Months Ended		6 Months Ended
In Millions, unless otherwise specified	Nov. 30, 2014	Nov. 30, 2013	Nov. 30, 2014	Nov. 30, 2013
Condensed Cash Flow Statements, Captions [Line Items]
Net sales	$843.60	$825.70	$1,618.40	$1,556.40
Cash flows provided by (used in) operating activities			162.7	170.9
Proceeds from sales/maturities of investments			15.2	19
Purchases of investments			-16.3	-19.6
Capital expenditures			-132.1	-98.5
Payments to Acquire Businesses, Net of Cash Acquired			0.6	0.8
Net cash used in investing activities			-133.8	-248.6
Payments under senior secured credit facilities			-8	-14.9
Proceeds under revolvers			205	159.3
Payments under revolvers			-20	-7
Proceeds from senior notes due 2020 and term loans			0	870.5
Retirement of term loans			-180	-1,091.60
Payment of fees related to refinancing activities			0	15.5
Net cash provided by (used in) financing activities			-2.7	-101.2
Effect of exchange rate changes on cash			2.7	-0.5
Increase (decrease) in cash and cash equivalents			28.9	-179.4
Cash and cash equivalents, beginning of period			247.6	355.6
Cash and cash equivalents, end of period	276.5	176.2	276.5	176.2
Cost of sales	183.8	255.1	399.7	463.1
Gross Profit	659.8	570.6	1,218.70	1,093.30
Selling, general and administrative expense	367.7	340.4	729.4	653.7
Research and development expense	42.9	41.4	85.7	78.9
Amortization	79.6	75.2	151.5	150.7
Operating Income (Loss)	169.6	113.6	252.1	210
Interest expense	78.5	105.7	158.6	193.3
Other Nonoperating Income (Expense)	2.1	-3.7	6.3	-5.9
Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Extraordinary Items, Noncontrolling Interest	93.2	4.2	99.8	10.8
Net income	89.8	4.9	97.1	36
Other comprehensive income (loss)	-136.1	37.1	-180.3	55.3
Comprehensive Income (Loss), Net of Tax, Attributable to Parent	-46.3	42	-83.2	91.3
Biomet, Inc [Member]
Condensed Cash Flow Statements, Captions [Line Items]
Net sales	0	0	0	0
Cash flows provided by (used in) operating activities			3	96.5
Proceeds from sales/maturities of investments			0	0
Purchases of investments			0	0
Capital expenditures			0	0
Other			0	0
Net cash used in investing activities			0	0
Payments under senior secured credit facilities				-14.9
Proceeds under revolvers			205	155
Payments under revolvers			-20
Proceeds from senior notes due 2020 and term loans				870.5
Retirement of term loans			-180	-1,091.60
Payment of fees related to refinancing activities				15.5
Other			-8	0
Net cash provided by (used in) financing activities			-3	-96.5
Effect of exchange rate changes on cash			0	0
Increase (decrease) in cash and cash equivalents			0	0
Cash and cash equivalents, beginning of period			0	0
Cash and cash equivalents, end of period	0	0	0	0
Cost of sales	0	0	0	0
Gross Profit	0	0	0	0
Selling, general and administrative expense	0	0	0	0
Research and development expense	0	0	0	0
Amortization	0	0	0	0
Operating Income (Loss)	0	0	0	0
Interest expense	78.5	106.1	158.6	193.1
Other Nonoperating Income (Expense)	0	-4.8	0	-4.8
Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Extraordinary Items, Noncontrolling Interest	-78.5	-110.9	-158.6	-197.9
Tax expense (benefit)	-29.8	-42.1	-60.3	-75.2
Equity in earnings of subsidiaries	138.5	73.7	195.4	158.7
Net income	89.8	4.9	97.1	36
Other comprehensive income (loss)	-136.1	8.8	-180.3	22.3
Comprehensive Income (Loss), Net of Tax, Attributable to Parent	-46.3	13.7	-83.2	58.3
Guarantor [Member]
Condensed Cash Flow Statements, Captions [Line Items]
Net sales	532.5	510.6	1,041.30	992
Cash flows provided by (used in) operating activities			60.9	278.5
Proceeds from sales/maturities of investments			0	19
Purchases of investments			0	-19.6
Capital expenditures			-74.3	-53.9
Other			-0.6	-0.8
Net cash used in investing activities			-74.9	-204.1
Payments under senior secured credit facilities				0
Proceeds under revolvers			0	0
Payments under revolvers			0
Proceeds from senior notes due 2020 and term loans				0
Retirement of term loans			0	0
Payment of fees related to refinancing activities				0
Other			0.3	0.3
Net cash provided by (used in) financing activities			0.3	0.3
Effect of exchange rate changes on cash			0	0
Increase (decrease) in cash and cash equivalents			-13.7	74.7
Cash and cash equivalents, beginning of period			101.8	35.3
Cash and cash equivalents, end of period	88.1	110	88.1	110
Cost of sales	158.5	221.5	364.7	402.2
Gross Profit	374	289.1	676.6	589.8
Selling, general and administrative expense	238.5	209.6	469.7	403.5
Research and development expense	32	30.3	63.4	58.2
Amortization	60.6	61.8	116.1	123.1
Operating Income (Loss)	42.9	-12.6	27.4	5
Interest expense	0	0	0	0
Other Nonoperating Income (Expense)	-5.9	1.2	-11.1	3.5
Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Extraordinary Items, Noncontrolling Interest	37	-11.4	16.3	8.5
Tax expense (benefit)	14	-4.3	6.1	3.3
Equity in earnings of subsidiaries	0	0	0	0
Net income	23	-7.1	10.2	5.2
Other comprehensive income (loss)	0	0	0.1	0
Comprehensive Income (Loss), Net of Tax, Attributable to Parent	23	-7.1	10.3	5.2
Non-Guarantors [Member]
Condensed Cash Flow Statements, Captions [Line Items]
Net sales	311.1	315.1	577.1	564.4
Cash flows provided by (used in) operating activities			98.8	-204.1
Proceeds from sales/maturities of investments			15.2	0
Purchases of investments			-16.3	0
Capital expenditures			-57.8	-44.6
Other			0	0.1
Net cash used in investing activities			-58.9	-44.5
Payments under senior secured credit facilities				0
Proceeds under revolvers			0	4.3
Payments under revolvers			0
Proceeds from senior notes due 2020 and term loans				0
Retirement of term loans			0	0
Payment of fees related to refinancing activities				0
Other			0	-9.3
Net cash provided by (used in) financing activities			0	-5
Effect of exchange rate changes on cash			2.7	-0.5
Increase (decrease) in cash and cash equivalents			42.6	-254.1
Cash and cash equivalents, beginning of period			145.8	320.3
Cash and cash equivalents, end of period	188.4	66.2	188.4	66.2
Cost of sales	25.3	33.6	35	60.9
Gross Profit	285.8	281.5	542.1	503.5
Selling, general and administrative expense	129.2	130.8	259.7	250.2
Research and development expense	10.9	11.1	22.3	20.7
Amortization	19	13.4	35.4	27.6
Operating Income (Loss)	126.7	126.2	224.7	205
Interest expense	0	-0.4	0	0.2
Other Nonoperating Income (Expense)	8	-0.1	17.4	-4.6
Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Extraordinary Items, Noncontrolling Interest	134.7	126.5	242.1	200.2
Tax expense (benefit)	19.2	45.7	56.9	46.7
Equity in earnings of subsidiaries	0	0	0	0
Net income	115.5	80.8	185.2	153.5
Other comprehensive income (loss)	-135.7	28.3	-183.6	33
Comprehensive Income (Loss), Net of Tax, Attributable to Parent	-20.2	109.1	1.6	186.5
Eliminations [Member]
Condensed Cash Flow Statements, Captions [Line Items]
Net sales	0	0	0	0
Cash flows provided by (used in) operating activities			0	0
Proceeds from sales/maturities of investments			0
Purchases of investments			0
Capital expenditures			0	0
Other			0	0
Net cash used in investing activities			0	0
Payments under senior secured credit facilities				0
Proceeds under revolvers			0	0
Payments under revolvers			0
Proceeds from senior notes due 2020 and term loans				0
Retirement of term loans			0	0
Payment of fees related to refinancing activities				0
Other			0	0
Net cash provided by (used in) financing activities			0	0
Effect of exchange rate changes on cash			0	0
Increase (decrease) in cash and cash equivalents			0	0
Cash and cash equivalents, beginning of period			0	0
Cash and cash equivalents, end of period	0	0	0	0
Cost of sales	0	0	0	0
Gross Profit	0	0	0	0
Selling, general and administrative expense	0	0	0	0
Research and development expense	0	0	0	0
Amortization	0	0	0	0
Operating Income (Loss)	0	0	0	0
Interest expense	0	0	0	0
Other Nonoperating Income (Expense)	0	0	0	0
Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Extraordinary Items, Noncontrolling Interest	0	0	0	0
Tax expense (benefit)	0	0	0	0
Equity in earnings of subsidiaries	-138.5	-73.7	-195.4	-158.7
Net income	-138.5	-73.7	-195.4	-158.7
Other comprehensive income (loss)	135.7	0	183.5	0
Comprehensive Income (Loss), Net of Tax, Attributable to Parent	-2.8	-73.7	-11.9	-158.7
Biomet, Inc. [Member]
Condensed Cash Flow Statements, Captions [Line Items]
Net sales	843.6	825.7	1,618.40	1,556.40
Cash flows provided by (used in) operating activities			162.7	170.9
Proceeds from sales/maturities of investments			15.2	19
Purchases of investments			-16.3	-19.6
Capital expenditures			-132.1	-98.5
Payments to Acquire Businesses, Net of Cash Acquired			0.6	0.8
Other			-0.6	-0.7
Net cash used in investing activities			-133.8	-248.6
Payments under senior secured credit facilities			-8	-14.9
Proceeds under revolvers			205	159.3
Payments under revolvers			-20	-7
Proceeds from senior notes due 2020 and term loans			0	870.5
Retirement of term loans			-180	-1,091.60
Payment of fees related to refinancing activities			0	15.5
Other			-7.7	-9
Net cash provided by (used in) financing activities			-2.7	-101.2
Effect of exchange rate changes on cash			2.7	-0.5
Increase (decrease) in cash and cash equivalents			28.9	-179.4
Cash and cash equivalents, beginning of period			247.6	355.6
Cash and cash equivalents, end of period	276.5	176.2	276.5	176.2
Cost of sales	183.8	255.1	399.7	463.1
Gross Profit	659.8	570.6	1,218.70	1,093.30
Selling, general and administrative expense	367.7	340.4	729.4	653.7
Research and development expense	42.9	41.4	85.7	78.9
Amortization	79.6	75.2	151.5	150.7
Operating Income (Loss)	169.6	113.6	252.1	210
Interest expense	78.5	105.7	158.6	193.3
Other Nonoperating Income (Expense)	2.1	-3.7	6.3	-5.9
Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Extraordinary Items, Noncontrolling Interest	93.2	4.2	99.8	10.8
Tax expense (benefit)	3.4	-0.7	2.7	-25.2
Equity in earnings of subsidiaries	0	0	0	0
Net income	89.8	4.9	97.1	36
Other comprehensive income (loss)	-136.1	37.1	-180.3	55.3
Comprehensive Income (Loss), Net of Tax, Attributable to Parent	-46.3	42	-83.2	91.3
Lanx, Inc. [Member]
Condensed Cash Flow Statements, Captions [Line Items]
Payments to Acquire Businesses, Net of Cash Acquired			0	148.8
Lanx, Inc. [Member] | Biomet, Inc [Member]
Condensed Cash Flow Statements, Captions [Line Items]
Payments to Acquire Businesses, Net of Cash Acquired				0
Lanx, Inc. [Member] | Guarantor [Member]
Condensed Cash Flow Statements, Captions [Line Items]
Payments to Acquire Businesses, Net of Cash Acquired				148.8
Lanx, Inc. [Member] | Non-Guarantors [Member]
Condensed Cash Flow Statements, Captions [Line Items]
Payments to Acquire Businesses, Net of Cash Acquired				0
Lanx, Inc. [Member] | Eliminations [Member]
Condensed Cash Flow Statements, Captions [Line Items]
Payments to Acquire Businesses, Net of Cash Acquired				0
Lanx, Inc. [Member] | Biomet, Inc. [Member]
Condensed Cash Flow Statements, Captions [Line Items]
Payments to Acquire Businesses, Net of Cash Acquired			$0	$148.80

Restructuring_Detail

Restructuring (Detail) (USD $)	3 Months Ended								6 Months Ended
In Millions, unless otherwise specified	Nov. 30, 2014		Aug. 31, 2014		Nov. 30, 2013		Aug. 31, 2013		Nov. 30, 2014	Nov. 30, 2013
Restructuring and Related Activities [Abstract]
Employee severance costs	$3.20				$5.90				$5	$12.20
Restructuring Reserve [Roll Forward]
Restructuring reserve, beginning balance	23.1		42.5		10.6		8.9		42.5	8.9
Costs incurred and charged to expense	3.2		1.8		5.9		6.3
Costs paid or otherwise settled	-2.5		-21		-3.9		-5.3
Non-cash adjustments	0	[1]	-0.2	[1]	0.8	[1]	0.7	[1]
Restructuring reserve, ending balance	$23.80		$23.10		$13.40		$10.60		$23.80	$13.40
[1]	Primarily related to foreign currency fluctuations.

Contingencies_Detail

Contingencies (Detail)

0 Months Ended

3 Months Ended

0 Months Ended

1 Months Ended

0 Months Ended

6 Months Ended

0 Months Ended

In Millions, unless otherwise specified

Sep. 26, 2014

Mar. 26, 2012

Nov. 30, 2014

Sep. 26, 2014

Nov. 30, 2014

Jun. 05, 2014

Dec. 31, 2008

Nov. 30, 2014

31-May-14

Nov. 30, 2014

Nov. 30, 2014

31-May-14

Nov. 30, 2014

Dec. 19, 2014

USD ($)

USD ($)

Multi-District Litigation [Member]

Multi-District Litigation [Member]

Multi-District Litigation [Member]

Heraeus Litigation [Member]

Heraeus Litigation [Member]

All Products, Excluding Metal-On-Metal Hip Products [Member]

All Products, Excluding Metal-On-Metal Hip Products [Member]

Metal-On-Metal Hip Products [Member]

Metal-On-Metal Hip Products [Member]

Metal-On-Metal Hip Products [Member]

Metal-On-Metal Hip Products [Member]

Subsequent Event [Member]

claim

USD ($)

USD ($)

EUR (€)

EUR (€)

USD ($)

USD ($)

claim

USD ($)

USD ($)

Multi-District Litigation [Member]

Multi-District Litigation [Member]

claim

USD ($)

Loss Contingencies [Line Items]

Minimum time period for compliance with Deferred Prosecution Agreement

3 years

Minimum time period of international sales compliance monitor

18 months

Penalty paid

$5.60

Amount paid to settle claims

17.3

-50

11.25

-25

Claims filed

1,938

2,033

Minimum claims dismissed

479

Self insurance annual coverage limit

50

Third-party insurance coverage

100

Insurance recovery, range of possible recovery, maximum

75

Insurance recoveries

26.7

Insurance settlements receivable

48.3

Accrual amount for contingencies

33.1

39.1

100

123.5

Lawsuit seeking amount for damages

€ 30

Related_Parties_Detail

Related Parties (Detail) (USD $)

0 Months Ended

3 Months Ended

6 Months Ended

20 Months Ended

36 Months Ended

0 Months Ended

Sep. 25, 2007

Jun. 13, 2007

Nov. 30, 2014

Nov. 30, 2013

Nov. 30, 2014

Nov. 30, 2013

Sep. 05, 2011

Aug. 31, 2014

1-May-07

Apr. 22, 2014

Apr. 24, 2014

Sep. 05, 2007

Jul. 11, 2007

director

vote

Employee

non-voting_observer

Related Party Transaction [Line Items]

Offer price

$46

Borrowings to finance portion of the Offer and pay related fees and expenses

$4,181,000,000

Credit agreement maturity date

7/11/07

Percentage of outstanding Shares tendered to Purchaser

82.00%

Percentage of shareholders voted to approve the proposed merger

91.00%

Date of acquisition

25-Sep-07

Percentage of transaction fee on total enterprise value

1.00%

Percentage of annual monitoring fee on Company's annual Adjusted EBITDA

1.00%

1.00%

Total amount of Sponsor fees

3,100,000

3,000,000

5,700,000

5,400,000

Number of directors each Sponsor has the right to nominate

2

Number of non-voting observer each Sponsor is entitled to appoint

1

Minimum percentage of membership interests that the sponsors should hold

70.00%

Number of non-affiliate directors each Sponsor may appoint (one or more)

1

Number of votes each director has for purposes of any Board of Directors action

1

Consulting fee

250,000

Out-of-pocket fees and expenses relating to an off-site office and administrative support

100,000

Non competition time period following term of agreement

1 year

Amount paid under consulting agreement

100,000

0

100,000

100,000

Fee per participating employee per month

2

Number of employees enrolled in its health benefit plans

3,200

Percentage of purchase requirements

80.00%

Total amount of fees paid

100,000

200,000

100,000

500,000

Treasury shares acquired

0

0

0

0

Employee capital contributions

0

0

0

0

Minimum [Member]

Related Party Transaction [Line Items]

Out-of-pocket fees and expenses relating to an off-site office and administrative support

100,000

Maximum [Member]

Related Party Transaction [Line Items]

Out-of-pocket fees and expenses relating to an off-site office and administrative support

150,000

Equity Healthcare [Member]

Related Party Transaction [Line Items]

Payments made to Equity Healthcare

0

100,000

0

100,000

Core Trust Purchasing Group [Member]

Related Party Transaction [Line Items]

Term of participation agreement

5 years

One Time Merger Fee [Member] | Principal Stockholders [Member]

Related Party Transaction [Line Items]

Related Party Transaction, Amounts of Transaction

88,000,000

Termination Fee [Member] | Director [Member]

Related Party Transaction [Line Items]

Related Party Transaction, Amounts of Transaction

2,000,000

Biomet, Inc. [Member] | Biomet, Inc [Member]

Related Party Transaction [Line Items]

Cumulative ownership after all transactions

97.00%

Senior Secured Term Loan Facility [Member]

Related Party Transaction [Line Items]

Amount of credit agreement

$6,165,000,000